



10/088078
PCT/AU00/01193

Patent Office
Canberra

I, LEANNE MYNOTT, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PQ 3148 for a patent by COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION filed on 29 September 1999.

WITNESS my hand this
Third day of November 2000

LEANNE MYNOTT
TEAM LEADER EXAMINATION
SUPPORT AND SALES

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)





AUSTRALIA
Patents Act 1990

PROVISIONAL SPECIFICATION

Invention Title: ANTI CANCER AGENT AND METHOD OF
TREATMENT OF CANCER

Applicant: COMMONWEALTH SCIENTIFIC &
INDUSTRIAL RESEARCH ORGANISATION

The invention is described in the following statement.

ANTI CANCER AGENT AND METHOD OF TREATMENT OF CANCER

The present invention relates to the treatment of cancer and to compositions for use in treatment of cancer.

5

The search for anti-cancer agents has been, and remains, a major endeavour of the pharmaceutical industry, academic institutions and government agencies throughout the world. One of the significant problems with many cancer treatments is the severe adverse affects they have on the patient and non-cancerous tissues.

10


We have now found that phomopsin mycotoxins (hereafter referred to as phomopsins) and their derivatives exhibit potent anticancer activity. We have also found that phomopsins exhibit selective activity against liver cancer. Without wishing to be bound by theory we believe that phomopsins exhibit selectivity for liver cancers due to a tendency of phomopsin to accumulate in the liver. It will be appreciated that the selectivity of phomopsin in treatment of liver cancer is a significant advantage as it allows liver cancers to be targeted while minimising the effects on other tissues.

Phomopsin may however be utilised in treatment of cancers other than liver cancer by selecting formulations or derivatives of phomopsin which enhance selectivity of the drug for certain types of cancer cells or certain types of cancers. Derivatives of phomopsins may be formed which are conjugates with monoclonal antibodies. The monoclonal antibody may be produced by known methods to provide selectivity for cancer cells.

25

Phomopsins are characterised by a 13-member ring structure generally of formula I

30



wherein


R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are optional substituents and may be independently selected from the group consisting of hydrogen, aliphatic, aromatic, peptide chains and halogen.

5 X is aliphatic, hydrogen or halogen (preferably hydrogen); and

Y is aliphatic, hydrogen or halogen (preferably chlorine);


where present a peptide chain may be conjugated with a monoclonal antibody (Mab).

10 The preferred phomopsins and phomopsin derivatives are those containing the group of formula Ia:




20 In formula I and Ia R¹, R², R³, R⁵, R⁶ and R⁷ may typically be independently selected from hydrogen and aliphatic and R⁴ is generally a peptide. In one embodiment R⁴ is a peptide conjugated with an antibody, particularly a monoclonal antibody (Mab). More preferably R¹, R², R⁵ and R⁶ are lower aliphatic and R³ and R⁷ are hydrogen. Even more preferably R¹, R² and R⁶ are lower alkyl and R⁵ is lower alkyl or lower alkenyl. Most preferably R¹ is ethyl, R² is methyl, R³ is hydrogen, R⁵ is isopropyl or iso-propenyl and R⁶ is methyl. Where used herein the terms lower aliphatic, lower alkyl and, lower alkenyl include groups containing up to six carbon atoms and most preferably up to 4 carbon atoms.

30 The preferred stereochemistry of the compounds of formula Ia is as shown in formula Ib:




The group R⁴ is a peptide preferably a di- or tri-peptide which may be optionally bound to an antibody such as a monoclonal antibody. The preferred group R⁴ has the formula II:



wherein the dotted line represents an optional double bond;

R⁸ and R⁹ are independently selected from hydrogen and lower alkyl and more preferably R⁸ is methyl and R⁹ is ethyl;

R¹² is selected from the group consisting of amino, mono substituted amino, disubstituted amino and an amino acid residue particularly the group of formula III:



wherein R¹³ and R¹⁴ are hydrogen or together form a double bond and R¹⁵ is selected from the group consisting of hydroxy, amino, substituted amino or an antibody particularly Mab.


When R¹⁵ is an antibody or linked to an antibody it is preferred that R¹³ and R¹⁴ form a double bond providing a dehydroaspartic acid residue. A dehydroaspartic acid residue has been found to facilitate delivery of phomopsin via a Mab conjugate.

The carbon-nitrogen bond in the residue of formula III is relatively weak enabling an active phomopsin of formula Ia (wherein in the group of formula II R¹² is amino) to be released from the MAb once it becomes bound to cancer cells.


- 5 The most preferred phomopsin compounds are selected from phomopsin A, octahydrophomopsin A, iso-phomopsin and phomopsinamine A. These compounds have the formula set out below:

10

15




20



25

30



In one aspect the invention provides a pharmaceutical composition for treatment of cancer, preferably liver cancer, containing a phomopsin compound or derivative thereof or pharmaceutically acceptable salt of the phomopsin or derivative and a pharmaceutically acceptable carrier.

5

Salts of phomopsin such as the alkaline metal salts are reasonably water soluble. Aqueous solutions can be formed by dissolving the phomopsin in a dilute base such as sodium hydroxide to provide a neutral solution.

- 10 In another aspect the invention provides a method of treatment of a patient suffering cancer including administering to the patient a phomopsin compound or derivative thereof or pharmaceutically acceptable salt of the phomopsin or derivative.

The phomopsin compound may be administered by a variety of methods including
15 oral administration in the form of a syrup, capsule, tablet or the like, by injection or by intravenous infusion.

Preferably the compound is administered by intravenous infusion

- 20 In a further aspect the invention provides the use of a phomopsin compound as hereinbefore described for preparation of a pharmaceutical composition for treatment of cancer and in particular liver cancer.

Phomopsin compounds are produced by certain fungi, including Diaporthe toxicus
25 (formerly Phomopsis leptostromiformis) and Phomopsis emicis, or may be derived from these natural products.

The isolation of phomopsin A is described by C. Culvenor, J. Edgar and M. Mackay, Tetrahedron Vol. 45, No. 8 pp 2351 (1989). Preparation of derivatives of
30 phomopsins such as octahydrophomopsins are described by J. Edgar, J. Frahn, P. Cockrum and J. Culvenor in the paper "Lupinosis. The Chemistry and Biochemistry of the Phomopsins" Mycotoxins and Phycotoxins, collection of invited papers presented at the sixth International IUPAC Symposium on Mycotoxins and Phycotoxins, Pretoria, Rep. South Africa, 22-25 July 1985.

The activity of phomopsin is believed to be due in part to the strong binding of the compound to tubulin. This may disrupt cell mitosis by inhibiting tubulin formation and cause depolymerization of formed microtubules. It may be preferred in some cases to use phomopsin in combination therapy with one or more other anticancer drugs or therapies. The drugs used in combination with phomopsin may be selected to enhance results by providing complementary activity in binding to microtubules. Examples of possible drugs for use in combination with phomopsin include paclitaxel, vinblastine, vincristine and alkaloids.

The present invention will now be more fully described with reference to the following examples. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.

Example 1

The following data demonstrate, the anticancer activity of phomopsin A, octahydrophomopsin A, iso-phomopsin A and phomopsinamine A against 60 human cancer cell lines *in vitro*. Phomopsin A and octahydrophomopsin A were obtained by the method as described in the references referred to above.

Iso-phomopsin A and phomopsinamine were prepared as follows:

ISOLATION OF PHOMOPSIN A

Background:

The extraction process is designed to minimise difficulty and cost. The fermented seed is continuously extracted with recycling 15% methanol:water through an in line XAD (styrene divinylbenzene copolymer) column. The time required for adsorption of phomopsin A onto the XAD is quite lengthy, but requires minimal operator input. The timing of this step is not critical, hence can be adapted to suite operating conditions.

The phomopsin A has a relatively low solubility in 15% methanol. The procedure relies on the adsorption of phomopsin A on the XAD resin driving the solubility equilibrium of phomopsin A in the fermented seed toward dissolution. This

procedure reduces solvent usage, volumes to be handled and flammability hazards. The alternate method of extraction, without recycling would use 150+ litres of pure methanol for the initial extraction, involve a further concentration step (or dilution of the methanol extract to 900+L) then adsorption onto XAD. The current procedure
 5 uses 12 L methanol, requires minimal operation input for the adsorption phase and uses far less solvent (total volume 85L instead of 900+L).

The elution of the concentrated phomopsin A from the column is the first step in a 3 stage isolation to produce crystalline phomopsin A of 80-90% purity.

10

Phomopsin may be eluted from the collection using 15% methanol as a preliminary wash and 100% methanol to complete elution. Silica gel flash column chromatography may be used for purification. The column is conditioned using 5:95 ammonia:isopropanol and the concentrate dissolved in a minimum of 20:65:15
 15 ammonia:isopropanol:water. Phomopsin is eluted using this 3 solvent combination. Recrystallisation from boiling glacial acetic acid provides phomopsin in 80-90% purity.

PREPARATION OF *iso*-PHOMOPSIN A

20 **Materials:**

0.05M HgCl₂: 280 mg HgCl₂ dissolved in 2 ml H₂O (+50 µl 10M HCl).

Phomopsin A: 18.3 mg PhA dissolved in 2 ml H₂O (with puff of NH₃).

1M HCl

Method:

25 Phomopsin A (2.0 ml) was mixed with 0.05M HgCl₂ (1 ml) and 1M HCl (200 µl), total volume 3.2 ml, and left at room temperature for 5 hours. The solution was diluted to 8 ml then passed through a prepared C18 Maxi-clean SPE cartridge (900 mg) and washed with 7-8 ml H₂O. The Maxi-clean was then eluted with 8-9 ml MeOH and made to 10 ml. The aqueous eluate from the first C18 cartridge was reprocessed
 30 through a second C18 cartridge to check whether the first cartridge was overloaded. The MeOH eluate from the second cartridge had very little residue on drying and was not included in further processing.

The methanol eluate was evaporated to dryness and subject to HPLC analysis and preparative HPLC.

5 Needle contamination with mercuric chloride was enough to cause almost complete conversion to iso-phomopsin. A needle used for a solution containing mercuric chloride could not be used for phomopsin, even with exhaustive washing. The phomopsin - HgCl_2 reaction mixture could be pumped back and forth through a disposable needle (20-30 times), a sample removed for assay, and the remainder of the sample left at RT for 5 hours, with hourly sampling (if necessary).

10

PREPARATION OF PHOMOPSINAMINE

Phomopsin A (15.3 mg) was dissolved in 1M HCl and left at RT for 28 hours. The reaction mixture was diluted to 8 ml then passed through a strong anion exchange cartridge (SAX, 600 mg) to remove any unreacted phomopsin A (pH of solution expected to be @ 1.52). The aqueous eluate (+ washings) was then passed through a prepared C18 cartridge (900 mg), washed with H_2O (10 ml) then eluted with methanol (10 ml).

20 The methanol eluate was evaporated to dryness subject to HPLC analysis and preparative HPLC.

This method may be modified by sampling the reaction mixture after 5-6 hours, 24 hours and 28-30 hours. All washings and eluates may be assayed by HPLC to monitor the conversion of phomopsin to phomopsinamine.

25

The methods used are those employed by the United States National Cancer Institute (NCI) as a primary screen for discovering compounds with anticancer potential (Boyd and Paull, 1995). The data are presented in the standard format used by NCI to show, for each compound tested, the absolute and relative sensitivity of individual cancer cell lines to the compounds and to demonstrate reproducible and selective effects.

30

HOLLOW FIBER ASSAY FOR PRELIMINARY *IN VIVO* TESTING

The Biological Testing Branch of the Developmental Therapeutics Program has adopted a preliminary *in vivo* screening tool for assessing the potential anticancer activity of compounds identified by the large scale *in vivo* cell screen. For these assays, human tumour cells are cultivated in polyvinylidene fluoride (PVDF) hollow fibers, and a sample of each cell line is implanted into each of two physiologic compartments (intraperitoneal and subcutaneous) in mice. Each test mouse receives a total of 6 fibers (3 intraperitoneally and 3 subcutaneously) representing 3 distinct cancer cell lines. Three mice are treated with potential antitumor compounds at each of 2 test doses by the intraperitoneal route using a QD x 4 treatment schedule. Vehicle controls consist of 6 mice receiving the compound diluent only. The fiber cultures are collected on the day following the last day of treatment. To assess anticancer effects, viable cell mass is determined for each of the cell lines using a formazan dye (MTT) conversion assay. From this, the %T/C can be calculated using the average optical density of the compound treated samples divided by the average optical density of the vehicle controls. In addition, the net increase in cell mass can be determined for each sample as a sample of fiber cultures are assessed for viable cell mass on the day of implantation into mice. Thus, the cytostatic and cytocidal capacities of the test compound can be assessed.

Generally, each compound is tested against a minimum of 12 human cancer cell lines. This represents a total of 4 experiments since each experiment contains 3 cell lines. The data are reported as %T/C for each of the 2 compound doses against each of the cell lines with separate values calculated for the intraperitoneal and subcutaneous samples.

Compounds are selected for further *in vivo* testing in standard subcutaneous xenograft models on the basis of several hollow fiber assay criteria. These include: (1) a % T/C of 50 or less in 10 of the 48 possible test combinations (12 cell lines X 2 sites X 2 compound doses); (2) activity at a distance (intraperitoneal drug/subcutaneous culture) in a minimum of 4 of the 24 possible combinations; and/or (3) a net cell kill of 1 or more cell lines in either implant site. To simplify evaluation, a points system has been adopted which allows rapid viewing of the activity of a given compound. For this, a value of 2 is assigned for each compound dose which results in a 50% or greater reduction in viable cell mass. The

intraperitoneal and subcutaneous samples are scored separately so that criteria (1) and (2) can be evaluated. Compounds with a combined IP+SC score ≥ 20 , a SC score ≥ 8 or a net cell kill of one or more cell lines are referred for xenograft testing. These criteria were statistically validated by comparing the activity outcomes of > 80 randomly selected compounds in the hollow fiber assay and in the xenograft testing. This comparison indicated that there was a very low probability of missing an active compound if the hollow fiber assay were used as the initial *in vivo* screening tool. In addition to these criteria, other factors (e.g. unique structure, mechanism of action) may result in referral of a compound for standard xenograft testing without the compound meeting these criteria.

SCREENING DATA REPORT COMPONENTS

The Calculated Measurement of Effect: Percentage Growth (PG)

The measured effect of the compound on a cell line is currently calculated according to one or the other of the following two expressions:

If $(\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{tzero}}) \geq 0$, then

$$\text{PG} = 100 \times (\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{tzero}}) / (\text{Mean OD}_{\text{ctrl}} - \text{Mean OD}_{\text{tzero}})$$

If $(\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{tzero}}) < 0$, then

$$\text{PG} = 100 \times (\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{tzero}}) / \text{Mean OD}_{\text{tzero}}$$

Where:

Mean OD_{tzero} = The average of optical density measurements of SRB-derived color just before exposure of cells to the test compound.

Mean OD_{test} = The average of optical density measurements of SRB-derived color after 48 hours exposure of cells to the test compound.

Mean OD_{ctrl} = The average of optical density measurements of SRB-derived color after 48 hours with no exposure of cells to the test compound.

The Data Sheet:

This page of the data package represents the experimental data collected against each cell line. The first two columns describe the subpanel (e.g. leukemia) and cell line (e.g. CCRF-CEM) involved. The next two columns list the Mean OD_{tzero} and Mean OD_{ctrl}; the next five columns list the Mean OD_{test} for each of five different concentrations. Each concentration is expressed as the log₁₀ (molar or

µg/ml). The next five columns list the calculated PGs for each concentration. The response parameters GI50, TGI, and LC50 are interpolated values representing the concentrations at which the PG is +50, 0, and -50, respectively. Sometimes these response parameters cannot be obtained by interpolation. If, for instance, all of the PGs in a given row exceed +50, then none of the three parameters can be obtained by interpolation. In such a case, the value given for each response parameter is the highest concentration tested and is preceded by a ">" sign. This practice is extended similarly to the other possible situations where a response parameter cannot be obtained by interpolation.

Dose-Response Curves:

The dose-response curve page of the data package is created by plotting the PGs against the \log_{10} of the corresponding concentration for every cell line. The cell line curves are grouped by subpanel. Horizontal lines are provided at the PG values of +50, 0, and -50. The concentrations corresponding to points where the curves cross these lines are the GI50, TGI, and LC50, respectively.

The Mean Graphs:

Mean graphs facilitate visual scanning of data for potential patterns of selectivity for particular cell lines or for particular subpanels with respect to a selected response parameter. Differences in apparent selectivity patterns may occur for the same compound against the same cell lines when different parameters are compared. The mean graphs page of the data package shows mean graphs at each of the principal response parameters: GI50, TGI, and LC50. Bars extending to the right represent sensitivity of the cell line to the test agent in excess of the average sensitivity of all tested cell lines. Since the bar scale is logarithmic, a bar 2 units to the right implies the compound achieved the response parameter (e.g. GI50) for the cell line at a concentration one-hundredth the mean concentration required over all cell lines, and thus the cell line is unusually sensitive to that compound. Bars extending to the left correspondingly imply sensitivity less than the mean. If, for a particular drug and cell line, it was not possible to determine the desired response parameter by interpolation, the bar length shown in either the highest concentration tested (and the listed \log_{10} of the

response parameter will be preceded by a ">") or the lowest concentration tested (and the listed \log_{10} will be preceded by a "<").

5 The values at either limited (> or <) are also calculated in the mean used for the mean graph. Therefore, the mean used in the mean graph may not be the actual mean of the G150, for instance. For this reason, we shall refer to this value as the MG-MID (for mean graph midpoint).

National Cancer Institute Developmental Therapeutics Program

In-Vitro Testing Results










Contract #: 673162-H/0-2/9	Experiment ID: 9502RM16	Test Type: 8	Units: Molar
Report Date: March 28, 1995	Test Date: February 13, 1995	QNS: SHP	MC:
OMI: Phomopsin A	Stain Reagent: Dual-Pass	SSPL: 0FLC	

Panel/Cell Line	Time	Zero	Ctrl	Mean Optical Densities				Log10 Concentration				Percent Growth				G150	TGI	LC50
				-8.0	-7.0	-6.0	-5.0	-4.0	-8.0	-7.0	-6.0	-5.0	-4.0					
Leukemia																		
CCRF-CEM	0.634	1.663	1.645	1.745	1.640	0.979	0.479	99	106	96	34	-24	5.55E-06	3.79E-05	>1.00E-04			
HL-60 (TB)	0.592	1.636	1.651	1.645	1.363	0.494	0.337	101	101	76	-17	-43	1.90E-06	6.62E-06	>1.00E-04			
K-562	0.362	1.205	1.161	1.227	1.101	0.560	0.294	97	102	87	24	-23	3.66E-06	3.24E-05	>1.00E-04			
MOLT-4	0.666	1.747	1.733	1.761	1.696	1.143	0.995	99	103	95	43	29	7.33E-06	>1.00E-04	>1.00E-04			
RPMI-8226	0.735	1.450	1.531	1.516	1.472	0.992	0.700	111	109	103	36	-5	6.16E-06	7.61E-05	>1.00E-04			
SR	0.466	0.856	0.923	0.696	0.686	0.406	0.315	116	111	54	-16	-35	1.15E-06	5.66E-06	>1.00E-04			
Non-Small Cell Lung Cancer																		
A549/ATCC	0.377	1.362	1.363	1.369	1.055	0.681	0.546	102	103	69	31	17	3.14E-06	>1.00E-04	>1.00E-04			
EKVX	0.402	0.935	0.946	0.966	0.854	0.616	0.461	102	106	85	40	11	6.09E-06	>1.00E-04	>1.00E-04			
HOP-62	0.391	0.953	0.974	0.965	0.931	0.796	0.705	104	106	96	72	56	>1.00E-04	>1.00E-04	>1.00E-04			
HOP-92	0.761	1.260	1.329	1.350	1.309	1.217	1.211	114	116	110	91	50	>1.00E-04	>1.00E-04	>1.00E-04			
NCI-H226	0.607	0.690	0.910	0.946	0.854	0.562	0.435	107	121	67	-4	-26	2.55E-06	9.03E-06	>1.00E-04			
NCI-H23	0.419	1.205	1.246	1.224	1.214	1.003	0.717	105	102	101	74	36	4.65E-05	>1.00E-04	>1.00E-04			
NCI-H322M	0.624	1.629	1.653	1.612	1.567	0.931	0.702	102	96	94	30	6	4.92E-06	>1.00E-04	>1.00E-04			
NCI-H460	0.181	1.131	1.155	1.235	0.972	0.349	0.271	103	111	63	16	9	3.21E-06	>1.00E-04	>1.00E-04			
NCI-H522	0.413	0.954	0.966	0.963	0.952	0.513	0.328	103	105	100	16	-21	4.06E-06	2.97E-05	>1.00E-04			
Colon Cancer																		
COLO 205	0.326	1.242	1.303	1.010	0.849	0.151	0.068	107	75	57	-54	-79	1.15E-06	3.26E-06	5.21E-06			
HCC-2998	0.590	1.321	1.264	1.263	1.134	0.621	0.319	95	95	74	4	-46	2.23E-06	1.21E-05	>1.00E-04			
HCT-116	0.161	1.236	1.209	1.263	1.245	0.506	0.279	97	102	101	32	11	5.47E-06	>1.00E-04	>1.00E-04			
HCT-15	0.317	1.751	1.611	1.714	1.383	0.697	0.466	90	97	74	26	10	3.23E-06	>1.00E-04	>1.00E-04			
HT29	0.166	0.659	0.622	0.636	0.796	0.264	0.200	95	97	91	14	5	3.42E-06	>1.00E-04	>1.00E-04			
KH12	0.294	1.232	1.230	1.076	0.675	0.411	0.341	100	63	62	12	5	1.74E-06	>1.00E-04	>1.00E-04			
SK-620	0.156	1.016	0.962	1.077	1.023	0.692	0.533	96	107	101	62	44	4.56E-05	>1.00E-04	>1.00E-04			
Breast Cancer																		
SF-266	0.463	1.301	1.314	1.311	1.210	0.692	0.764	101	101	69	51	36	1.19E-05	>1.00E-04	>1.00E-04			
SF-295	0.400	1.077	1.122	1.066	0.900	0.540	0.454	107	102	74	21	6	2.61E-06	>1.00E-04	>1.00E-04			
SF-539	0.367	0.666	0.654	0.656	0.730	0.317	0.176	94	94	69	-16	-54	1.64E-06	6.17E-06	7.79E-05			
SNB-19	0.571	1.452	1.394	1.429	1.363	0.960	0.762	93	97	92	44	22	7.56E-06	>1.00E-04	>1.00E-04			
SNB-75	0.361	0.626	0.610	0.571	0.500	0.339	0.432	93	77	46	-11	21	6.46E-07		>1.00E-04			
U251	0.199	0.651	0.653	0.663	0.776	0.302	0.225	100	102	69	16	4	3.40E-06	>1.00E-04	>1.00E-04			
Sarcoma																		
LOX IMVI	0.191	1.076	0.966	1.053	0.922	0.574	0.372	90	97	82	43	20	6.71E-06	>1.00E-04	>1.00E-04			
MJLME-3H	0.464	0.952	0.956	0.914	0.760	0.619	0.566	101	92	65	32	25	2.76E-06	>1.00E-04	>1.00E-04			
MJ4	0.196	0.527	0.521	0.472	0.406	0.198	0.144	96	63	64	0	-27	1.65E-06	1.04E-05	>1.00E-04			
SK-MEL-2	0.746	1.404	1.363	1.373	1.297	0.954	0.616	97	95	84	32	11	4.45E-06	>1.00E-04	>1.00E-04			
SK-MEL-26	0.576	1.271	1.229	1.152	1.047	0.679	0.636	94	63	66	44	37	5.43E-06	>1.00E-04	>1.00E-04			
SK-MEL-5	0.034	1.051	1.053	0.916	0.522	0.344	0.264	100	67	46	30	23	6.69E-07	>1.00E-04	>1.00E-04			
UACC-257	0.536	1.126	1.205	1.145	0.962	0.669	0.948	113	104	72	60	70	>1.00E-04	>1.00E-04	>1.00E-04			
UACC-62	0.577	1.790	1.796	1.735	1.533	1.043	0.667	101	95	79	36	26	5.17E-06	>1.00E-04	>1.00E-04			
Ovarian Cancer																		
IGR-OV1	0.515	1.761	1.746	1.761	1.726	1.429	1.069	99	102	97	73	44	6.43E-05	>1.00E-04	>1.00E-04			
OVCA-3	0.293	0.611	0.620	0.756	0.623	0.350	0.313	102	97	64	11	4	1.62E-06	>1.00E-04	>1.00E-04			
OVCA-4	0.467	1.061	1.074	0.964	1.167	0.652	0.600	99	64	114	63	54	>1.00E-04	>1.00E-04	>1.00E-04			
OVCA-5	0.393	0.662	0.666	0.672	0.761	0.485	0.516	101	102	76	20	27	3.05E-06	>1.00E-04	>1.00E-04			
OVCA-6	0.267	0.947	0.914	0.943	0.925	0.692	0.320	95	99	97	61	6	1.69E-05	>1.00E-04	>1.00E-04			
SK-OV-3	0.466	0.975	0.995	0.961	0.621	0.565	0.525	104	97	70	19	11	2.45E-06	>1.00E-04	>1.00E-04			
Renal Cancer																		
766-0	0.200	0.913	0.949	0.640	0.628	0.385	0.325	105	90	86	26	16	4.14E-06	>1.00E-04	>1.00E-04			
A496	1.061	1.567	1.550	1.524	1.406	1.109	1.079	96	91	67	6	0	1.69E-06	9.31E-05	>1.00E-04			
ACHN	0.406	1.366	1.412	1.305	1.267	0.661	0.759	101	91	69	46	36	6.65E-06	>1.00E-04	>1.00E-04			
CAXI-1	0.466	0.940	0.691	0.664	0.762	0.641	0.597	90	66	63	37	26	3.07E-06	>1.00E-04	>1.00E-04			
RUF-393	0.704	1.545	1.469	1.438	1.113	0.913	1.034	91	67	49	25	39	9.20E-07	>1.00E-04	>1.00E-04			
SW12C	0.371	1.274	1.312	1.305	1.202	0.950	0.711	104	104	92	64	36	3.41E-05	>1.00E-04	>1.00E-04			
TK-10	0.627	1.221	1.166	1.227	1.134	1.032	0.939	94	101	65	66	53	>1.00E-04	>1.00E-04	>1.00E-04			
UO-31	0.593	1.442	1.424	1.367	1.369	1.134	0.997	96	94	91	64	46	7.06E-05	>1.00E-04	>1.00E-04			
Testate Cancer																		
PC-3	0.302	1.096	1.092	1.010	0.625	0.465	0.360	100	66	66	20	10	2.23E-06	>1.00E-04	>1.00E-04			
DU-145	0.339	1.061	1.122	1.073	0.617	0.396	0.296	106	102	66	6	-13	1.69E-06	2.42E-05	>1.00E-04			
Prostate Cancer																		
PC7	0.423	1.174	1.156	1.115	0.924	0.563	0.465	96	92	67	21	6	2.33E-06	>1.00E-04	>1.00E-04			
PC7/ADR-RES	0.330	0.907	0.696	0.904	0.647	0.609	0.407	99	99	90	46	13	9.19E-06	>1.00E-04	>1.00E-04			
MDA-MB-231/ATCC	0.402	0.660	0.954	0.665	0.919	0.634	0.421	99	101	93	77	2	2.31E-05	>1.00E-04	>1.00E-04			
RS 576T	0.664	1.319	1.337	1.350	1.324	1.165	1.205	104	107	101	71	75	>1.00E-04	>1.00E-04	>1.00E-04			
MDA-MB-435	0.320	0.961	0.966	0.647	0.427	0.174	0.065	96	60	16	-46	-60	2.93E-07	1.63E-06	1.34E-05			
MDA-N	0.214	0.752	0.715	0.596	0.152	0.030	0.045	93	71	-29	-66	-79	1.62E-07	5.11E-07	2.32E-06			
BT-549	0.476	0.622	0.622	0.653	0.665	0.664	0.666	100	121	112	60	56	>1.00E-04	>1.00E-04	>1.00E-04			
T-47D	0.711	2.002	1.666	2.094	1.626	1.252	1.655	91	107	71	42	73		>1.00E-04	>1.00E-04	>1.00E-04		

Dose Response Curves

Report Date: March 28, 1995

Test Date: February 15, 1990












National Cancer Institute Developmental Therapeutics Program

In-Vitro Testing Results

C: D-673162-H/0-1/2	Experiment ID: 9409SC89	Test Type: 8	Units: Molar
Report Date: October 27, 1994	Test Date: September 26, 1994	QNS:	MC:
DMI: PHOMOPSIN A	Stain Reagent: Dual-Pass	SSPL: 0FLC	


Anal/Cell Line	Time Zero	Ctrl	Log10 Concentration					Percent Growth					GI50	TGI	LC50
			-8.0	-7.0	-6.0	-5.0	-4.0	-6.0	-7.0	-6.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.250	0.853	0.758	0.769	0.734	0.244	0.132	84	86	80	-2	-47	2.33E-06	9.40E-06	>1.00E-04
HL-60 (TB)	0.213	0.837	0.679	0.764	0.686	0.147	0.073	75	88	76	-31	-65	1.75E-06	5.13E-06	3.56E-05
K-562	0.129	0.952	0.989	1.125	0.897	0.403	0.223	105	121	93	33	11	5.27E-06	>1.00E-04	>1.00E-04
MOLT-4	0.281	1.269	1.249	1.197	1.169	0.560	0.560	96	93	90	26	26	4.44E-06	>1.00E-04	>1.00E-04
RPMI-8226	0.196	0.763	0.782	0.732	0.689	0.247	0.144	103	94	87	9	-27	2.97E-06	1.78E-05	>1.00E-04
SR	0.238	1.549	1.414	1.390	1.387	0.572	0.487	90	88	86	25	19	4.03E-06	>1.00E-04	>1.00E-04
Non-Small Cell Lung Cancer															
A549/ATCC	0.361	1.606	1.696	1.649	1.386	0.782	0.678	107	103	82	34	25	4.62E-06	>1.00E-04	>1.00E-04
ECVX	0.686	1.638	1.701	1.629	1.562	1.239	1.117	107	99	92	58	45	4.20E-05	>1.00E-04	>1.00E-04
HOP-62	0.834	1.643	1.641	1.753	1.635	1.293	1.114	100	114	99	57	35	2.01E-05	>1.00E-04	>1.00E-04
H1226	0.591	0.976	0.924	0.916	0.961	0.720	0.564	87	85	96	34	-5	5.46E-06	7.59E-05	>1.00E-04
H23	0.455	1.551	1.565	1.566	1.417	0.674	0.447	101	101	88	20	-2	3.60E-06	6.30E-05	>1.00E-04
NCI-H322M	0.556	1.332	1.277	1.276	1.178	0.765	0.899	93	93	80	27	44	3.69E-06	>1.00E-04	>1.00E-04
NCI-H460	0.219	1.089	1.100	1.049	0.913	0.324	0.235	101	95	80	12	.	2.75E-06		
NCI-H522	0.434	1.047	1.062	1.062	1.004	0.492	0.343	102	102	93	9	-21	3.27E-06	2.04E-05	>1.00E-04
Colon Cancer															
COLO 205	0.206	0.993	0.985	1.055	0.750	0.152	0.116	99	108	69	-27	-44	1.58E-06	5.24E-06	>1.00E-04
HCC-2998	0.262	0.831	0.855	0.806	0.759	0.324	0.164	104	96	87	11	-37	3.09E-06	1.66E-05	>1.00E-04
HCT-116	0.230	1.467	1.507	1.415	1.405	0.631	0.417	102	94	93	32	15	5.06E-06	>1.00E-04	>1.00E-04
HCT-15	0.717	2.848	2.880	2.825	2.910	1.470	1.035	102	99	103	35	15	6.07E-06	>1.00E-04	>1.00E-04
HT29	0.148	0.784	0.753	0.754	0.730	0.126	0.071	95	95	92	-14	-52	2.48E-06	7.39E-06	8.68E-05
KML2	0.907	2.630	2.493	2.409	1.963	0.738	0.435	92	87	61	-19	-52	1.38E-06	5.85E-06	8.72E-05
SW-620	0.140	0.747	0.774	0.773	0.703	0.349	0.274	104	104	93	34	22	5.39E-06	>1.00E-04	>1.00E-04
CNS Cancer															
SF-266	0.367	1.090	1.120	1.132	0.994	0.660	0.486	104	106	87	40	16	6.20E-06	>1.00E-04	>1.00E-04
SF-295	0.554	1.306	1.303	1.263	1.111	0.302	0.258	100	94	74	-45	-53	1.59E-06	4.16E-06	3.70E-05
SF-539	0.517	1.546	1.539	1.568	1.526	0.844	0.481	99	102	98	32	-7	5.31E-06	6.61E-05	>1.00E-04
SNB-19	0.587	1.730	1.744	1.709	1.662	1.231	0.961	101	98	94	56	33	1.85E-05	>1.00E-04	>1.00E-04
SNB-75	0.367	0.848	0.767	0.629	0.502	0.440	0.444	63	55	28	15	16	1.49E-07	>1.00E-04	>1.00E-04
U251	0.191	0.840	0.862	0.830	0.781	0.357	0.247	103	98	91	26	9	4.23E-06	>1.00E-04	>1.00E-04
Melanoma															
LOX IMVI	0.279	1.166	1.180	1.243	1.164	0.689	0.611	101	106	100	46	37	8.46E-06	>1.00E-04	>1.00E-04
M14	0.250	0.620	0.617	0.657	0.530	0.320	0.172	99	110	76	19	-31	2.82E-06	2.38E-05	>1.00E-04
SK-MEL-2	0.563	1.464	1.350	1.395	1.232	0.855	0.709	67	92	74	32	16	3.80E-06	>1.00E-04	>1.00E-04
SK-MEL-28	0.305	0.827	0.804	0.816	0.664	0.496	0.573	96	96	69	37	51		>1.00E-04	>1.00E-04
SK-MEL-5	0.354	1.726	1.806	1.745	1.094	0.656	0.491	106	101	54	22	10	1.32E-06	>1.00E-04	>1.00E-04
UACC-257	0.709	1.849	1.826	1.759	1.565	1.004	1.189	98	92	75	26	42	3.23E-06	>1.00E-04	>1.00E-04
Ovarian Cancer															
IGROV1	0.346	1.442	1.490	1.646	1.535	0.968	0.646	104	119	109	57	27	1.70E-05	>1.00E-04	>1.00E-04
OVCA-5	0.377	0.866	0.886	0.888	0.798	0.498	0.475	99	100	82	24	19	3.55E-06	>1.00E-04	>1.00E-04
OVCA-8	0.550	2.445	2.538	3.068	2.519	1.674	1.121	105	133	104	59	30	2.09E-05	>1.00E-04	>1.00E-04
SK-OV-3	0.423	0.677	0.851	0.940	0.826	0.543	0.637	94	114	89	26	47	4.19E-06	>1.00E-04	>1.00E-04
Renal Cancer															
786-0	0.434	1.893	1.766	1.843	1.865	0.988	0.686	91	97	98	38	17	6.30E-06	>1.00E-04	>1.00E-04
498	0.561	0.995	0.991	0.996	0.922	0.636	0.534	99	100	83	17	-5	3.19E-06	6.00E-05	>1.00E-04
ACHN	0.306	1.166	1.150	1.082	1.077	0.674	0.488	98	90	90	43	21	7.03E-06	>1.00E-04	>1.00E-04
SN12C	0.636	1.595	1.645	1.596	1.627	1.204	0.903	105	100	103	59	28	1.97E-05	>1.00E-04	>1.00E-04
TK-10	0.399	1.046	1.049	1.085	1.037	0.996	0.757	100	106	98	92	55	>1.00E-04	>1.00E-04	>1.00E-04
Prostate Cancer															
PC-3	0.952	3.382	3.359	3.378	3.041	1.463	1.322	99	100	86	21	15	3.58E-06	>1.00E-04	>1.00E-04
DU-145	0.459	1.630	1.615	1.686	1.434	0.711	0.688	99	105	83	22	20	3.46E-06	>1.00E-04	>1.00E-04
Breast Cancer															
MCF7	0.759	1.241	1.224	1.244	1.009	0.486	0.379	98	100	76	23	12	3.13E-06	>1.00E-04	>1.00E-04
MCF7/ADR-RES	0.517	1.452	1.460	1.497	1.351	0.831	0.448	97	100	86	.	.	2.84E-06	>1.00E-04	>1.00E-04
MDA-MB-231/ATCC	0.614	1.663	1.673	1.663	1.636	1.322	0.939	99	96	96	66	30	3.33E-06	>1.00E-04	>1.00E-04
HS 578T	0.586	1.199	1.278	1.255	1.072	0.729	0.612	113	109	79	23	4	4.57E-07	1.05E-05	>1.00E-04
MDA-MB-435	1.282	1.264	1.166	1.079	0.616	0.288	0.218	90	81	34	1	-23	4.53E-07	1.73E-06	5.58E-06
MDA-N	0.332	1.412	1.441	1.423	0.583	0.084	0.124	100	100	100	65	49	8.72E-05	>1.00E-04	>1.00E-04
BT-549	0.606	1.201	1.242	1.262	1.200	0.995	0.864	95	96	74	32	56		>1.00E-04	>1.00E-04
T-47D	0.775	2.347	2.271	2.323	1.932	1.275	1.656								



Mean Graphs

Report Date: October 21, 1974










Test Date: September 1974



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

Contract #: J73164-J/0-2/11	Experiment ID: 9502RM16	Test Type: 8	Units: Molar
Report Date: March 28, 1995	Test Date: February 13, 1995	QNS: SHP	MC:
MI: Iso-phomopsin A	Stain Reagent: Dual-Pass	SSPL: OFLC	

Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration						Percent Growth						GI50	TGI	LC50
			-8.0	-7.0	-6.0	-5.0	-4.0	-3.0	-2.0	-1.0	0.0	1.0	2.0	3.0			
Leukemia																	
CCRF-CEM	0.634	1.762	1.792	1.825	1.730	0.920	0.502	103	106	97	25	-21	4.54E-06	3.55E-05	>1.00E-04		
HL-60 (TB)	0.592	1.622	1.571	1.622	1.447	0.477	0.351	95	100	83	-15	-41	2.10E-06	6.46E-06	>1.00E-04		
K-562	0.362	1.370	1.372	1.411	1.295	0.567	0.317	100	104	92	15	-17	3.76E-06	3.34E-05	>1.00E-04		
MOLT-4	0.688	1.845	1.870	1.847	1.862	1.201	0.965	102	100	101	44	24	7.96E-06	>1.00E-04	>1.00E-04		
RFMI-6226	0.735	1.589	1.671	1.673	1.567	0.696	0.786	110	110	57	19	6	4.02E-06	>1.00E-04	>1.00E-04		
SR	0.486	1.032	1.031	1.013	0.711	0.414	0.377	100	96	41	-15	-22	6.95E-07	5.44E-06	>1.00E-04		
Non-Small Cell Lung Cancer																	
A549/ATCC	0.377	1.339	1.374	1.336	1.120	0.692	0.556	104	100	77	33	19	4.11E-06	>1.00E-04	>1.00E-04		
ECVX	0.402	1.029	0.990	1.034	1.006	0.677	0.536	94	101	96	44	22	7.61E-06	>1.00E-04	>1.00E-04		
HOP-62	0.391	0.693	0.864	0.863	0.639	0.664	0.529	94	94	89	54	26	1.46E-05	>1.00E-04	>1.00E-04		
HOP-92	0.761	1.116	1.101	1.101	1.031	0.995	1.066	96	96	76	66	66	>1.00E-04	>1.00E-04	>1.00E-04		
NCI-H226	0.607	0.864	0.900	0.890	0.834	0.573	0.446	114	110	88	-6	-27	2.55E-06	6.73E-06	>1.00E-04		
NCI-H23	0.419	1.166	1.198	1.202	1.038	0.774	0.709	104	105	83	48	39	6.51E-06	>1.00E-04	>1.00E-04		
NCI-H322H	0.624	1.566	1.627	1.551	1.529	0.926	0.752	106	98	96	32	14	5.26E-06	>1.00E-04	>1.00E-04		
NCI-H460	0.181	1.263	1.192	1.314	1.035	0.363	0.226	93	105	79	20	4	3.07E-06	>1.00E-04	>1.00E-04		
NCI-H522	0.413	1.073	1.081	1.050	0.992	0.514	0.395	101	97	86	15	-4	3.32E-06	6.00E-05	>1.00E-04		
Colon Cancer																	
COLO 205	0.326	1.333	1.236	1.089	0.770	0.217	0.097	90	76	44	-34	-70	6.44E-07	3.66E-06	2.75E-05		
HCC-2996	0.590	1.266	1.252	1.248	1.142	0.545	0.214	96	97	82	-6	-64	2.26E-06	6.23E-06	5.66E-05		
HCT-116	0.161	1.304	1.227	1.169	1.061	0.406	0.211	93	88	79	21	4	3.17E-06	>1.00E-04	>1.00E-04		
HCT-15	0.317	1.667	1.626	1.637	1.464	0.711	0.512	97	98	85	29	14	4.23E-06	>1.00E-04	>1.00E-04		
HT29	0.166	0.631	0.624	0.626	0.733	0.233	0.207	99	100	65	10	6	2.94E-06	>1.00E-04	>1.00E-04		
IMR12	0.294	1.445	1.343	1.296	0.636	0.464	0.277	91	67	47	15	-6	6.55E-07	5.23E-05	>1.00E-04		
SW-620	0.156	0.691	0.670	0.667	0.766	0.450	0.410	97	99	83	40	35	5.65E-06	>1.00E-04	>1.00E-04		
MS Cancer																	
SF-266	0.463	1.431	1.373	1.352	1.314	0.966	0.617	94	92	86	52	37	1.36E-05	>1.00E-04	>1.00E-04		
SF-295	0.400	1.038	1.007	1.039	0.864	0.479	0.356	95	100	73	12	-11	2.36E-06	3.37E-05	>1.00E-04		
SF-539	0.367	0.660	0.667	0.648	0.745	0.275	0.123	101	97	76	-29	-66	1.76E-06	5.26E-06	3.41E-05		
SNB-19	0.571	1.365	1.360	1.362	1.292	0.930	0.733	97	100	65	44	20	7.37E-06	>1.00E-04	>1.00E-04		
SNB-75	0.361	0.626	0.619	0.636	0.568	0.370	0.529	97	104	64	-3	60	.	.	>1.00E-04		
U251	0.199	0.893	0.676	0.867	0.736	0.276	0.226	98	96	77	11	4	2.56E-06	>1.00E-04	>1.00E-04		
Melanoma																	
LOX IMVI	0.191	0.962	0.963	0.980	0.921	0.551	0.430	98	100	92	45	30	6.01E-06	>1.00E-04	>1.00E-04		
MALME-3H	0.464	1.037	1.039	0.976	0.631	0.611	0.563	100	89	64	26	17	2.33E-06	>1.00E-04	>1.00E-04		
M14	0.196	0.569	0.571	0.496	0.453	0.215	0.146	101	80	69	5	-26	1.96E-06	1.45E-05	>1.00E-04		
SK-MEL-2	0.746	1.368	1.331	1.360	1.212	0.667	0.653	94	99	75	23	17	3.01E-06	>1.00E-04	>1.00E-04		
SK-MEL-26	0.576	1.166	1.146	1.114	1.043	0.617	0.721	93	88	77	40	24	5.22E-06	>1.00E-04	>1.00E-04		
SK-MEL-5	0.034	1.014	1.006	0.885	0.622	0.320	0.375	99	67	60	29	35	2.11E-06	>1.00E-04	>1.00E-04		
UACC-257	0.536	1.297	1.175	1.234	1.133	0.685	0.977	84	92	76	46	56	.	>1.00E-04	>1.00E-04		
UACC-62	0.577	1.662	1.806	1.610	1.639	1.150	0.946	96	96	63	45	29	7.21E-06	>1.00E-04	>1.00E-04		
Ovarian Cancer																	
IGR-OV1	0.515	1.689	1.661	1.656	1.605	1.192	0.937	96	97	93	56	36	2.26E-05	>1.00E-04	>1.00E-04		
OVCAR-3	0.293	0.905	0.886	0.846	0.572	0.314	0.244	97	90	46	3	-17	7.97E-07	1.47E-05	>1.00E-04		
OVCAR-4	0.467	1.176	1.151	1.121	1.026	0.906	0.796	97	92	79	62	47	6.05E-05	>1.00E-04	>1.00E-04		
OVCAR-5	0.393	0.867	0.872	0.884	0.730	0.467	0.495	97	99	66	15	21	2.20E-06	>1.00E-04	>1.00E-04		
OVCAR-8	0.267	1.196	1.256	1.255	1.252	0.950	0.563	106	106	106	74	34	3.93E-05	>1.00E-04	>1.00E-04		
SK-OV-3	0.466	1.011	0.962	0.966	0.662	0.595	0.503	95	92	76	23	6	3.13E-06	>1.00E-04	>1.00E-04		
Renal Cancer																	
786-O	0.200	0.949	0.901	0.829	0.794	0.442	0.317	94	84	79	32	16	4.19E-06	>1.00E-04	>1.00E-04		
A496	1.061	1.413	1.354	1.359	1.371	1.079	0.903	82	84	67	0	-16	2.67E-06	9.94E-06	>1.00E-04		
ACHN	0.406	1.460	1.471	1.547	1.470	0.993	0.917	101	106	101	56	46	6.11E-05	>1.00E-04	>1.00E-04		
CAKI-1	0.466	0.950	0.904	0.971	0.862	0.695	0.690	90	104	82	47	46	6.32E-06	>1.00E-04	>1.00E-04		
RUF-393	0.704	1.562	1.562	1.603	1.361	1.070	1.013	100	102	75	42	35	5.59E-06	>1.00E-04	>1.00E-04		
SN12C	0.371	1.335	1.291	1.265	1.270	0.555	0.640	95	93	93	61	26	2.11E-05	>1.00E-04	>1.00E-04		
TK-10	0.627	1.091	1.094	1.113	1.076	0.771	0.956	101	105	97	56	71	>1.00E-04	>1.00E-04	>1.00E-04		
UO-31	0.593	1.476	1.452	1.440	1.439	1.166	1.016	97	96	96	67	46	7.61E-05	>1.00E-04	>1.00E-04		
Prostate Cancer																	
PC-3	0.302	1.164	1.161	1.115	0.892	0.504	0.503	100	94	66	23	23	2.56E-06	>1.00E-04	>1.00E-04		
DU-145	0.339	1.029	1.077	1.026	0.832	0.324	0.306	107	100	72	-5	-9	1.92E-06	6.71E-06	>1.00E-04		
Breast Cancer																	
MCF7	0.423	1.139	1.131	1.123	1.068	0.649	0.509	99	96	90	32	12	4.84E-06	>1.00E-04	>1.00E-04		
MCF7/ADR-RES	0.330	1.037	0.996	1.001	0.544	0.640	0.376	94	95	87	44	7	7.19E-06	>1.00E-04	>1.00E-04		
MDA-MB-231/ATCC	0.406	0.926	0.915	0.963	0.666	0.766	0.502	97	110	92	73	18	2.60E-05	>1.00E-04	>1.00E-04		
HS 578T	0.664	1.396	1.391	1.236	1.236	1.119	1.174	99	70	70	46	58	.	>1.00E-04	>1.00E-04		
MDA-MB-435	0.320	1.266	1.314	1.164	0.653	0.206	0.099	103	67	34	-35	-59	5.06E-07	3.13E-06	2.76E-05		
MDA-N	0.214	0.746	0.764	0.654	0.179	0.035	0.026	103	62	-16	-64	-66	2.13E-07	6.63E-07	3.16E-06		
BT-549	0.476	0.606	0.615	0.600	0.774	0.640	0.634	102	96	50	50	46	9.72E-06	>1.00E-04	>1.00E-04		
T-47D	0.711	2.153	1.927	2.015	1.610	1.303	1.466	64	50	76	41	52	.	>1.00E-04	>1.00E-04		












PanelCell Line	Log ₁₀ TCID ₅₀	Log ₁₀ TCID ₅₀	Log ₁₀ TCID ₅₀	Log ₁₀ TCID ₅₀
Labware				
CCRE-CLN	-5.14	-4.45	> 4.00	> 4.00
ML-NATD	-5.64	-5.10	> 4.00	> 4.00
K 162	-5.42	-4.46	> 4.00	> 4.00
KNH T 4	-5.10	> 4.00	> 4.00	> 4.00
RPMI 8236	-5.40	> 4.00	> 4.00	> 4.00
SR	-6.16	-5.26	> 4.00	> 4.00
Non-Sensitized				
AS50A/TC	-5.70	> 4.00	> 4.00	> 4.00
FRVX	-5.12	> 4.00	> 4.00	> 4.00
HOP-62	-4.84	> 4.00	> 4.00	> 4.00
HOP-92	> 4.00	> 4.00	> 4.00	> 4.00
NCTH226	-5.39	-5.06	> 4.00	> 4.00
NCTH23	-5.01	> 4.00	> 4.00	> 4.00
NCTH23M	-5.28	> 4.00	> 4.00	> 4.00
NCTH24	-5.51	> 4.00	> 4.00	> 4.00
NCTH222	-5.48	-4.22	> 4.00	> 4.00
Green-Cover				
COLO 204	-6.19	-5.14	> 4.00	-4.56
HCC-2994	-5.65	-5.08	> 4.00	-4.73
HCT-116	-5.50	> 4.00	> 4.00	> 4.00
HCT-15	-5.17	> 4.00	> 4.00	> 4.00
HCT9	-5.51	> 4.00	> 4.00	> 4.00
KH12	-6.07	-4.78	> 4.00	> 4.00
SW620	-5.23	> 4.00	> 4.00	> 4.00
S-Gover	-4.86	> 4.00	> 4.00	> 4.00
ST-264	-5.62	-4.47	> 4.00	> 4.00
SF-205	-5.35	-5.28	> 4.00	> 4.00
SF-319	-5.13	> 4.00	> 4.00	> 4.00
SWP-16	-5.39	> 4.00	> 4.00	> 4.00
SWP-15	-5.39	> 4.00	> 4.00	> 4.00
U251	-5.39	> 4.00	> 4.00	> 4.00
Midstream				
LOX INVI	-5.10	> 4.00	> 4.00	> 4.00
MALME 3M	-5.64	> 4.00	> 4.00	> 4.00
NH4	-5.30	-4.84	> 4.00	> 4.00
SK-MEL-2	-5.52	> 4.00	> 4.00	> 4.00
SK-MEL-38	-5.78	> 4.00	> 4.00	> 4.00
SK-MEL-5	-5.64	> 4.00	> 4.00	> 4.00
UACC-251	-5.14	> 4.00	> 4.00	> 4.00
UACC-62	-5.14	> 4.00	> 4.00	> 4.00
Ovarian Cancer				
KOR-OV1	-4.65	> 4.00	> 4.00	> 4.00
OVCA-R-1	-6.10	-4.81	> 4.00	> 4.00
OVCA-R-4	-4.22	> 4.00	> 4.00	> 4.00
OVCA-R-5	-5.66	> 4.00	> 4.00	> 4.00
OVCA-R-8	-4.41	> 4.00	> 4.00	> 4.00
SK-OV-1	-5.50	> 4.00	> 4.00	> 4.00
Breast Cancer				
T468	-5.34	> 4.00	> 4.00	> 4.00
A208	-5.57	-5.00	> 4.00	> 4.00
ACT10	-4.21	> 4.00	> 4.00	> 4.00
CAK11	-5.04	> 4.00	> 4.00	> 4.00
BT-203	-5.25	> 4.00	> 4.00	> 4.00
SK-BR-3	-4.64	> 4.00	> 4.00	> 4.00
TK-20	> 4.00	> 4.00	> 4.00	> 4.00
UO-31	-4.11	> 4.00	> 4.00	> 4.00
Prostate Cancer				
PC-1	-5.39	> 4.00	> 4.00	> 4.00
DU-145	-5.72	-5.06	> 4.00	> 4.00
Brain Cancer				
NCT7	-5.12	> 4.00	> 4.00	> 4.00
AGC7/AD8-RL5	-5.14	> 4.00	> 4.00	> 4.00
NDA-MR-1/4/17	-4.39	> 4.00	> 4.00	> 4.00

National Cancer Institute Developmental Therapeutic Program

In Vitro Testing Results


Protocol: D- J164-J/0-1/4	Experiment ID: 9409SC89	Test Type: 8	Units: Molar
Port Date: October 27, 1994	Test Date: September 26, 1994	QNS:	MC:
Assay: ISO-PHOMOPSIN A	Stain Reagent: Dual-Pass	SSPL: 0FLC	

Cell Line	Time Zero	Ctrl	Log10 Concentration					Percent Growth					GI50	TGI	LC50
			-8.0	-7.0	-6.0	-5.0	-4.0	-6.0	-7.0	-8.0	-5.0	-4.0			
Leukemia															
CCRF-CEM	0.250	0.646	0.867	0.826	0.799	0.292	0.143	103	97	92	7	-43	3.12E-06	1.36E-05	>1.00E-04
HL-60 (TB)	0.213	0.710	0.741	0.700	0.701	0.150	0.086	106	96	96	-29	-59	2.39E-06	5.69E-06	4.99E-05
K-562	0.129	0.726	0.896	0.866	0.799	0.279	0.159	126	123	112	25	5	5.16E-06	>1.00E-04	>1.00E-04
MOLT-4	0.261	1.162	1.135	1.210	1.215	0.689	0.327	97	105	106	46	5	6.66E-06	>1.00E-04	>1.00E-04
RPMI-8226	0.196	0.764	0.822	0.809	0.710	0.196	0.168	106	104	67	0	-14	2.69E-06	1.04E-05	>1.00E-04
SR	0.238	1.562	1.504	1.544	1.488	0.609	0.307	96	99	94	26	5	4.67E-06	>1.00E-04	>1.00E-04
Non-Small Cell Lung Cancer															
A549/ATCC	0.361	1.402	1.444	1.430	1.301	0.683	0.476	104	103	90	31	11	4.76E-06	>1.00E-04	>1.00E-04
EKVX	0.668	1.701	1.728	1.712	1.663	1.334	1.279	103	101	98	64	58	>1.00E-04	>1.00E-04	>1.00E-04
HOP-62	0.634	1.738	1.696	1.579	1.546	1.310	1.022	95	62	79	53	21	1.21E-05	>1.00E-04	>1.00E-04
HCI-H226	0.591	0.929	0.913	0.906	0.963	0.724	0.500	95	93	110	39	-15	7.04E-06	5.22E-05	>1.00E-04
HCI-H23	0.455	1.575	1.566	1.630	1.493	0.875	0.636	99	105	93	37	16	5.93E-06	>1.00E-04	>1.00E-04
HCI-H322M	0.556	1.391	1.351	1.395	1.267	0.840	0.986	95	100	85	34	51	>1.00E-04	>1.00E-04	>1.00E-04
HCI-H460	0.219	1.062	1.023	1.025	0.940	0.281	0.150	95	96	85	7	-32	2.84E-06	1.54E-05	>1.00E-04
HCI-H522	0.434	1.065	1.065	1.059	1.034	0.500	0.104	100	99	95	10	-76	3.40E-06	1.32E-05	5.00E-05
Colon Cancer															
COLO 205	0.208	0.975	0.991	1.024	0.792	0.114	0.109	102	106	76	-45	-48	1.64E-06	4.24E-06	>1.00E-04
MCC-2998	0.262	0.673	0.848	0.866	0.826	0.356	0.171	96	99	92	15	-35	3.55E-06	2.03E-05	>1.00E-04
HCT-116	0.230	1.417	1.419	1.549	1.405	0.583	0.300	100	111	99	30	6	5.09E-06	>1.00E-04	>1.00E-04
HCT-15	0.717	2.647	2.851	2.880	2.893	1.573	1.050	100	102	102	40	16	6.95E-06	>1.00E-04	>1.00E-04
HCT-29	0.146	0.617	0.806	0.804	0.774	0.103	0.110	98	98	93	-30	-26	2.24E-06	5.68E-06	>1.00E-04
HCT-29	0.907	1.983	2.156	1.962	1.577	0.611	0.283	116	96	62	-33	-69	1.35E-06	4.53E-06	3.02E-05
HCT-29	0.140	0.690	0.683	0.687	0.618	0.269	0.149	99	99	87	23	2	3.82E-06	>1.00E-04	>1.00E-04
ES Cancer															
ST-268	0.367	1.294	1.313	1.235	1.173	0.792	0.651	102	94	87	46	31	7.91E-06	>1.00E-04	>1.00E-04
ST-295	0.554	1.239	1.239	1.193	1.158	0.354	0.267	100	93	88	-36	-52	2.03E-06	5.12E-06	7.57E-05
ST-539	0.517	1.466	1.449	1.435	1.309	0.789	0.576	96	95	62	26	6	3.91E-06	>1.00E-04	>1.00E-04
SNB-19	0.567	1.709	1.709	1.684	1.590	1.230	1.007	100	96	89	57	37	2.34E-05	>1.00E-04	>1.00E-04
SNB-75	0.367	0.601	0.730	0.810	0.827	0.466	0.523	84	102	106	23	36	4.72E-06	>1.00E-04	>1.00E-04
U251	0.191	0.674	0.852	0.829	0.755	0.293	0.152	97	93	63	15	-20	3.03E-06	2.65E-05	>1.00E-04
Leiomyoma															
LOX IMVI	0.279	1.142	1.136	1.106	1.061	0.653	0.444	99	96	91	43	19	7.22E-06	>1.00E-04	>1.00E-04
M14	0.250	0.509	0.452	0.456	0.370	0.235	0.106	76	61	46	-6	-56	7.86E-07	7.74E-06	7.13E-05
SK-MEL-2	0.563	1.347	1.349	1.305	1.191	0.705	0.566	100	95	80	16	0	3.06E-06	>1.00E-04	>1.00E-04
SK-MEL-26	0.305	0.940	0.894	0.906	0.800	0.602	0.577	93	95	78	47	43	7.89E-06	>1.00E-04	>1.00E-04
SK-MEL-5	0.354	1.476	1.666	1.591	0.613	0.347	0.370	117	110	41	-2	1	7.37E-07	.	>1.00E-04
UACC-257	0.709	1.939	1.918	1.889	1.751	0.960	1.035	96	96	85	20	27	3.46E-06	>1.00E-04	>1.00E-04
Ovarian Cancer															
IGROV1	0.346	1.494	1.546	1.561	1.429	0.914	0.660	105	106	94	49	27	9.72E-06	>1.00E-04	>1.00E-04
OVCA-5	0.377	0.957	0.970	0.954	0.928	0.546	0.523	102	100	95	30	25	4.87E-06	>1.00E-04	>1.00E-04
OVCA-8	0.550	2.624	2.695	2.769	2.718	1.919	1.214	103	107	105	66	32	2.95E-05	>1.00E-04	>1.00E-04
SK-OV-3	0.423	0.662	0.882	0.866	0.802	0.530	0.576	105	106	86	24	35	3.86E-06	>1.00E-04	>1.00E-04
Anal Cancer															
786-O	0.434	1.623	1.726	1.743	1.813	0.992	0.760	93	94	99	40	24	6.82E-06	>1.00E-04	>1.00E-04
A498	0.561	0.917	0.906	0.893	0.901	0.634	0.572	97	93	95	21	3	4.04E-06	>1.00E-04	>1.00E-04
ACHN	0.306	1.169	1.181	1.125	1.087	0.701	0.487	101	95	91	46	21	8.02E-06	>1.00E-04	>1.00E-04
SN12C	0.636	1.662	1.687	1.655	1.676	1.306	0.884	102	99	101	65	24	2.36E-05	>1.00E-04	>1.00E-04
TK-10	0.399	1.066	1.072	1.090	1.072	0.981	0.789	101	103	101	67	58	>1.00E-04	>1.00E-04	>1.00E-04
Prostate Cancer															
PC-3	0.952	3.351	3.364	3.498	2.967	1.625	1.382	101	106	85	28	18	4.11E-06	>1.00E-04	>1.00E-04
DU-145	0.459	1.560	1.627	1.678	1.526	0.630	0.516	106	111	97	16	5	3.77E-06	>1.00E-04	>1.00E-04
Breast Cancer															
ADR-RES	0.259	1.163	1.204	1.109	0.900	0.442	0.291	102	92	69	20	3	2.46E-06	>1.00E-04	>1.00E-04
MDA-MB-231/ATCC	0.517	1.302	1.347	1.375	1.266	0.670	0.535	106	109	95	19	2	3.96E-06	>1.00E-04	>1.00E-04
MS 578T	0.614	1.660	1.680	1.663	1.733	1.286	0.884	102	100	107	64	26	2.35E-05	>1.00E-04	>1.00E-04
MDA-MB-435	0.586	1.116	1.132	1.009	0.951	0.786	0.750	103	60	69	36	31	4.03E-06	>1.00E-04	>1.00E-04
MDA-N	0.283	1.202	1.185	1.255	0.813	0.226	0.307	98	106	58	-20	3	1.25E-06	.	>1.00E-04
BT-549	0.332	1.546	1.562	1.449	0.841	0.310	0.209	103	92	42	-7	-37	6.90E-07	7.30E-06	>1.00E-04
T-47D	0.606	1.199	1.295	1.247	1.333	1.026	0.794	116	106	123	71	32	3.44E-05	>1.00E-04	>1.00E-04
	0.775	2.137	2.196	2.079	2.174	1.353	1.352	104	96	103	42	42	7.46E-06	>1.00E-04	>1.00E-04



Mean Graphs










Report Date: October 21, 1974



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

673163 -I/0-2/10	Experiment ID: 9502RM16	Test Type: 8	Units: Molar
Report Date: March 28, 1995	Test Date: February 13, 1995	QNS: SHP	MC:
DMI: Octahydrophomopsin A	Stain Reagent: Dual-Pass	SSPL: OFLO	

Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration					Percent Growth					G150	TGI	GI50	
			-6.0	-7.0	-8.0	-9.0	-10.0	-6.0	-7.0	-8.0	-9.0	-10.0				
Leukemia																
CCRF-CEM	0.634	1.663	1.656	1.663	1.595	0.922	0.423	96	102	93	28	-33	4.61E-06	>1.00E-04	>1.00E-04	
HL-60 (TB)	0.592	1.636	1.633	1.440	1.562	0.616	0.389	100	81	93	2	-34	2.98E-06	>1.00E-04	>1.00E-04	
K-562	0.362	1.209	1.242	1.206	1.201	0.606	0.303	104	100	99	27	-21	4.62E-06	>1.00E-04	>1.00E-04	
MOLT-4	0.686	1.747	1.766	1.735	1.780	1.196	0.966	104	99	103	48	24	9.20E-06	>1.00E-04	>1.00E-04	
RPMI-6226	0.735	1.450	1.406	1.355	1.423	1.015	0.711	94	87	96	39	-3	6.46E-06	>1.00E-04	>1.00E-04	
SR	0.486	0.856	0.776	0.627	0.666	0.444	0.318	78	92	54	-9	-35	1.16E-06	>1.00E-04	>1.00E-04	
Non-Small Cell Lung Cancer																
A549/ATCC	0.377	1.362	1.405	1.289	1.366	0.942	0.579	104	93	101	57	21	1.59E-05	>1.00E-04	>1.00E-04	
ERVX	0.402	0.935	0.961	0.896	0.695	0.680	0.523	101	93	93	52	23	1.16E-05	>1.00E-04	>1.00E-04	
HOP-62	0.391	0.953	0.893	0.896	0.670	0.699	0.507	89	90	85	55	21	1.36E-05	>1.00E-04	>1.00E-04	
HOP-92	0.761	1.260	1.251	1.202	1.220	1.013	1.142	98	86	92	51	76	>1.00E-04	>1.00E-04	>1.00E-04	
NCI-H226	0.607	0.890	0.914	0.902	0.895	0.671	0.524	108	104	102	23	-14	4.52E-06	>1.00E-04	>1.00E-04	
NCI-H23	0.419	1.205	1.156	1.170	1.063	0.664	0.634	94	96	85	57	37	1.66E-05	>1.00E-04	>1.00E-04	
NCI-H322M	0.624	1.629	1.615	1.607	1.616	1.366	0.799	99	96	99	74	17	2.65E-05	>1.00E-04	>1.00E-04	
NCI-H460	0.161	1.131	1.177	1.144	1.171	0.609	0.319	105	101	104	45	15	6.24E-06	>1.00E-04	>1.00E-04	
NCI-H522	0.413	0.954	1.000	0.969	0.965	0.561	0.360	106	103	102	27	-13	4.96E-06	>1.00E-04	>1.00E-04	
Colon Cancer																
COLO 205	0.526	1.242	1.250	1.183	1.006	0.450	0.285	101	94	74	13	-13	2.49E-06	>1.00E-04	>1.00E-04	
HCC-2998	0.590	1.321	1.301	1.316	1.349	0.944	0.514	97	100	104	46	-13	5.33E-06	>1.00E-04	>1.00E-04	
HCT-116	0.161	1.236	1.291	1.234	1.249	0.616	0.341	105	100	101	42	17	7.39E-06	>1.00E-04	>1.00E-04	
HCT-15	0.317	1.751	1.602	1.646	1.477	0.960	0.626	90	93	81	45	22	7.20E-06	>1.00E-04	>1.00E-04	
HT29	0.166	0.659	0.640	0.633	0.663	0.592	0.219	97	96	101	61	6	1.63E-05	>1.00E-04	>1.00E-04	
KM12	0.294	1.232	1.237	1.193	1.227	0.672	0.484	101	96	99	40	20	6.66E-06	>1.00E-04	>1.00E-04	
SW-620	0.156	1.016	1.016	0.955	0.947	0.652	0.466	100	93	92	56	36	2.24E-05	>1.00E-04	>1.00E-04	
ONS Cancer																
SF-266	0.463	1.301	1.309	1.262	1.166	0.696	0.647	101	96	86	52	46	2.07E-05	>1.00E-04	>1.00E-04	
SF-295	0.400	1.077	1.029	0.933	0.903	0.551	0.401	93	79	74	22	0	1.94E-06	>1.00E-04	>1.00E-04	
SF-539	0.367	0.666	0.802	0.633	0.619	0.393	0.176	83	90	67	1	-55	2.66E-06	>1.00E-04	6.29E-05	
SNB-19	0.571	1.452	1.464	1.481	1.490	1.013	0.769	101	103	104	50	23	1.02E-05	>1.00E-04	>1.00E-04	
SNB-75	0.361	0.628	0.626	0.633	0.510	0.341	0.420	99	102	52	-11	16	1.06E-06	>1.00E-04	>1.00E-04	
U251	0.199	0.651	0.868	0.625	0.629	0.396	0.255	103	96	97	30	9	5.02E-06	>1.00E-04	>1.00E-04	
Melanoma																
LOX IMVI	0.191	1.076	0.996	0.997	0.945	0.593	0.416	91	91	85	45	25	7.64E-06	>1.00E-04	>1.00E-04	
MALME-3M	0.464	0.952	0.949	0.934	0.677	0.691	0.594	99	96	84	46	27	6.09E-06	>1.00E-04	>1.00E-04	
M14	0.196	0.527	0.496	0.521	0.522	0.337	0.214	90	98	96	43	5	7.35E-06	>1.00E-04	>1.00E-04	
SK-MEL-2	0.746	1.404	1.406	1.377	1.356	1.007	0.624	101	96	93	40	12	6.41E-06	>1.00E-04	>1.00E-04	
SK-MEL-26	0.576	1.271	1.313	1.201	1.106	0.913	0.675	106	90	76	46	43	6.77E-06	>1.00E-04	>1.00E-04	
SK-MEL-5	0.034	1.051	1.156	1.123	0.765	0.402	0.319	110	107	72	36	26	4.11E-06	>1.00E-04	>1.00E-04	
UACC-257	0.536	1.126	1.159	1.155	0.975	0.919	1.057	105	105	74	65	66	>1.00E-04	>1.00E-04	>1.00E-04	
UACC-62	0.577	1.790	1.836	1.739	1.633	0.959	0.796	104	96	67	31	16	4.65E-06	>1.00E-04	>1.00E-04	
Ovarian Cancer																
IGR-OV1	0.515	1.761	1.666	1.697	1.663	1.362	1.032	94	95	94	66	42	4.76E-05	>1.00E-04	>1.00E-04	
OVCAR-3	0.293	0.611	0.625	0.606	0.745	0.452	0.359	103	99	67	31	13	4.57E-06	>1.00E-04	>1.00E-04	
OVCAR-4	0.467	1.061	1.120	1.016	1.043	0.967	0.631	106	90	94	85	59	>1.00E-04	>1.00E-04	>1.00E-04	
OVCAR-5	0.393	0.862	0.893	0.862	0.667	0.662	0.514	107	104	105	62	26	2.12E-05	>1.00E-04	>1.00E-04	
OVCAR-6	0.267	0.947	0.932	0.937	0.911	0.743	0.393	98	99	95	70	19	2.45E-05	>1.00E-04	>1.00E-04	
SK-OV-3	0.466	0.975	0.994	0.923	0.965	0.666	0.519	104	90	96	43	10	7.56E-06	>1.00E-04	>1.00E-04	
Renal Cancer																
766-0	0.200	0.913	1.003	0.886	0.644	0.543	0.436	113	96	90	46	33	9.01E-06	>1.00E-04	>1.00E-04	
A496	1.061	1.567	1.566	1.546	1.569	1.331	1.179	104	96	100	51	20	1.11E-05	>1.00E-04	>1.00E-04	
ACHN	0.406	1.396	1.401	1.430	1.436	1.206	0.923	100	103	104	81	52	>1.00E-04	>1.00E-04	>1.00E-04	
CAKI-1	0.466	0.940	0.916	0.806	0.792	0.636	0.616	95	72	69	36	52	3.77E-06	>1.00E-04	>1.00E-04	
RXF-393	0.704	1.545	1.504	1.469	1.362	1.136	1.054	95	93	81	52	42	1.44E-05	>1.00E-04	>1.00E-04	
SN12C	0.371	1.274	1.196	1.213	1.201	0.936	0.734	91	93	92	63	40	3.67E-05	>1.00E-04	>1.00E-04	
TK-10	0.627	1.221	1.172	1.207	1.122	1.167	0.977	92	96	83	91	59	>1.00E-04	>1.00E-04	>1.00E-04	
UO-31	0.593	1.442	1.440	1.370	1.431	1.226	1.030	100	92	99	75	52	>1.00E-04	>1.00E-04	>1.00E-04	
Prostate Cancer																
PC-3	0.302	1.096	1.130	1.086	1.042	0.636	0.395	104	99	93	42	12	7.00E-06	>1.00E-04	>1.00E-04	
DU-145	0.339	1.061	1.064	1.036	1.016	0.465	0.334	100	97	94	17	-1	3.75E-06	>1.00E-04	>1.00E-04	
Breast Cancer																
MCF7	0.423	1.174	1.207	1.176	1.130	0.706	0.771	104	100	94	36	46	6.12E-06	>1.00E-04	>1.00E-04	
MCF7/ADR-RES	0.330	0.907	0.917	0.897	0.689	0.664	0.462	102	96	97	61	23	1.96E-05	>1.00E-04	>1.00E-04	
MDA-MB-231/ATCC	0.406	0.960	0.945	0.780	0.805	0.764	0.529	97	67	72	64	22	2.15E-05	>1.00E-04	>1.00E-04	
HS 578T	0.664	1.319	1.334	1.262	1.261	1.096	1.243	103	92	67	51	63	>1.00E-04	>1.00E-04	>1.00E-04	
MDA-MB-435	0.320	0.961	0.965	0.910	0.564	0.239	0.109	101	89	40	-25	-66	6.22E-07	>1.00E-04	4.05E-05	
MDA-N	0.214	0.752	0.670	0.651	0.275	0.049	0.042	65	61	11	-77	-60	2.60E-07	>1.00E-04	4.94E-06	
BT-549	0.476	0.622	0.901	0.649	0.609	0.636	0.609	123	108	96	46	36	6.41E-06	>1.00E-04	>1.00E-04	
T-47D	0.711	2.002	1.964	1.999	1.622	1.470	1.709	99	100	66	59	77	>1.00E-04	>1.00E-04	>1.00E-04	












[illegible]

National Cancer Institute Developmental Therapeutics Program


In-Vitro Testing Results

Cell Line: D-673163-I/0-1/3	Experiment ID: 9409SC89	Test Type: 8	Units: Molar
Test Date: October 27, 1994	Test Date: September 26, 1994	QNS:	MC:
Target: OCTAHYDROPHOMOPSIN A	Stain Reagent: Dual-Pass	SSPL: 0FLC	

Cell Line	Time		Log10 Concentration						Percent Growth						GI50	TGI	LC50
	Zero	Ctrl	-6.0	-7.0	-8.0	-9.0	-10.0	-11.0	-12.0	-13.0	-14.0	-15.0	-16.0	-17.0			
Cell Line																	
Kemira	0.250	0.846	0.785	0.823	0.736	0.301	0.242	90	96	62	6	-3	2.71E-06	5.32E-05	>1.00E-04		
CCR6-CEM	0.213	0.710	0.741	0.686	0.649	0.160	0.109	106	95	86	-25	-49	2.16E-06	5.99E-06	>1.00E-04		
HL-60 (IB)	0.129	0.726	0.727	0.774	0.682	0.261	0.215	100	106	92	22	14	4.00E-06	>1.00E-04	>1.00E-04		
K-562	0.281	1.162	1.167	1.266	1.202	0.624	0.454	103	112	105	39	20	6.79E-06	>1.00E-04	>1.00E-04		
MOLT-4	0.196	0.784	0.841	0.776	0.692	0.239	0.131	110	95	84	7	-33	2.79E-06	1.51E-05	>1.00E-04		
RPMT-8226	0.236	1.562	1.483	1.509	1.456	0.600	0.432	94	96	92	27	15	4.46E-06	>1.00E-04	>1.00E-04		
SR																	
-5- Cell Lung Cancer																	
A549	0.361	1.402	1.450	1.442	1.370	0.849	0.507	105	104	97	47	14	6.66E-06	>1.00E-04	>1.00E-04		
ECVX	0.686	1.701	1.649	1.673	1.583	1.317	1.133	95	97	86	62	44	4.64E-05	>1.00E-04	>1.00E-04		
HOP-62	0.834	1.738	1.762	1.704	1.779	1.486	1.222	103	96	105	72	43	5.72E-05	>1.00E-04	>1.00E-04		
NCI-H226	0.591	0.929	0.879	0.843	0.876	0.702	0.461	85	75	85	33	-22	4.68E-06	3.97E-05	>1.00E-04		
NCI-H23	0.455	1.575	1.684	1.778	1.623	1.229	0.593	110	116	104	69	12	2.17E-05	>1.00E-04	>1.00E-04		
NCI-H322M	0.556	1.391	1.394	1.383	1.313	0.969	0.775	100	99	91	49	26	5.70E-06	>1.00E-04	>1.00E-04		
NCI-H460	0.219	1.062	1.058	1.051	1.028	0.462	0.239	99	99	96	29	2	4.63E-06	>1.00E-04	>1.00E-04		
NCI-H522	0.434	1.065	1.059	1.059	0.992	0.435	0.468	99	99	88	.	5	6.40E-06	>1.00E-04	>1.00E-04		
Colon Cancer																	
COLO 205	0.208	0.975	0.956	0.972	0.745	0.216	0.037	97	100	70	1	-62	1.95E-06	1.03E-05	4.11E-05		
HCC-2996	0.262	0.873	1.115	1.211	1.084	0.687	0.221	.	.	135	.	-16	1.33E-05	6.16E-05	>1.00E-04		
HCT-116	0.230	1.417	1.467	1.447	1.413	0.721	0.392	104	103	100	41	14	7.11E-06	>1.00E-04	>1.00E-04		
HCT-15	0.717	2.847	2.756	2.780	2.767	1.946	1.060	96	97	97	58	16	1.53E-05	>1.00E-04	>1.00E-04		
HT29	0.148	0.817	0.772	0.755	0.749	0.351	0.191	93	91	90	30	6	4.67E-06	>1.00E-04	>1.00E-04		
KM12	0.907	1.983	2.066	2.236	2.404	1.586	0.833	108	124	139	63	-6	1.53E-05	7.68E-05	>1.00E-04		
SW-620	0.140	0.690	0.664	0.678	0.618	0.325	0.319	95	96	87	34	32	4.92E-06	>1.00E-04	>1.00E-04		
Colon Cancer																	
SF-268	0.367	1.294	1.305	1.290	1.161	0.764	0.572	101	100	86	43	22	6.78E-06	>1.00E-04	>1.00E-04		
SF-295	0.554	1.239	1.154	1.158	1.046	0.405	0.194	88	68	72	-27	-65	1.67E-06	5.35E-06	4.04E-05		
SF-539	0.517	1.486	1.496	1.437	1.440	0.780	0.353	101	95	95	27	-32	4.62E-06	2.89E-05	>1.00E-04		
SNB-19	0.587	1.709	1.704	1.675	1.696	1.254	1.014	100	97	99	59	36	2.76E-05	>1.00E-04	>1.00E-04		
SNB-75	0.367	0.801	0.757	0.850	0.753	0.342	0.483	90	111	89	-7	27	2.55E-06	.	>1.00E-04		
U251	0.191	0.874	0.848	0.869	0.806	0.327	0.185	96	95	90	20	-3	3.72E-06	7.30E-05	>1.00E-04		
Anoma																	
LOX IHVI	0.279	1.142	1.113	1.138	1.069	0.724	0.617	97	100	92	52	39	1.33E-05	>1.00E-04	>1.00E-04		
M14	0.250	0.509	0.510	0.431	0.493	0.313	0.122	101	70	94	24	-51	4.27E-06	2.10E-05	9.70E-05		
SK-MEL-2	0.563	1.347	1.436	1.420	1.391	0.858	1.033	111	109	106	38	60	.	>1.00E-04	>1.00E-04		
SK-MEL-28	0.305	0.940	0.972	0.901	0.743	0.489	0.564	105	94	69	29	41	2.96E-06	>1.00E-04	>1.00E-04		
SK-MEL-5	0.354	1.476	1.402	1.533	0.864	0.388	0.267	93	105	45	3	-19	6.35E-07	1.37E-05	>1.00E-04		
UACC-257	0.709	1.939	1.910	1.898	1.755	1.149	1.159	96	97	85	36	37	5.14E-06	>1.00E-04	>1.00E-04		
Ovarian Cancer																	
IGROV1	0.346	1.494	1.587	1.579	1.480	0.947	0.733	106	107	99	52	34	1.35E-05	>1.00E-04	>1.00E-04		
OVCAR-5	0.377	0.957	0.968	0.921	0.933	0.710	0.518	102	94	96	57	24	1.68E-05	>1.00E-04	>1.00E-04		
OVCAR-8	0.550	2.624	2.741	2.595	2.626	1.832	1.160	106	95	100	62	29	2.32E-05	>1.00E-04	>1.00E-04		
OVCAR-3	0.423	0.862	0.796	0.851	0.770	0.543	0.377	85	96	79	27	-11	3.63E-06	5.21E-05	>1.00E-04		
Leuk Cancer																	
786-0	0.434	1.623	1.673	1.963	2.204	1.748	1.181	104	110	127	95	54	>1.00E-04	>1.00E-04	>1.00E-04		
A498	0.561	0.917	0.933	0.917	0.926	0.734	0.617	104	100	103	49	16	9.42E-06	>1.00E-04	>1.00E-04		
ACHN	0.306	1.169	1.158	1.138	1.048	0.830	0.495	99	96	86	61	22	1.69E-05	>1.00E-04	>1.00E-04		
SN12C	0.636	1.662	1.651	1.625	1.575	1.283	0.924	99	96	92	63	26	2.36E-05	>1.00E-04	>1.00E-04		
TK-10	0.399	1.068	1.047	1.042	1.073	0.980	0.739	97	96	101	87	51	>1.00E-04	>1.00E-04	>1.00E-04		
Epithelial Cancer																	
PC-3	0.952	3.351	3.083	3.359	3.104	1.852	1.447	95	101	91	37	21	5.76E-06	>1.00E-04	>1.00E-04		
PC-145	0.459	1.560	1.610	1.654	1.500	0.778	0.440	105	106	95	29	-4	4.77E-06	7.50E-05	>1.00E-04		
Test Cancer																	
MJ1	0.205	1.222	1.222	1.253	1.261	0.576	0.498	115	106	108	34	26	6.13E-06	>1.00E-04	>1.00E-04		
NCI7/ADF-R3	0.519	1.302	1.357	1.352	1.342	1.026	0.499	107	106	101	66	-14	1.58E-05	6.57E-05	>1.00E-04		
MDA-MB-231/ATCC	0.614	1.660	1.659	1.611	1.482	1.166	0.850	100	95	85	53	23	1.23E-05	>1.00E-04	>1.00E-04		
HS 578T	0.586	1.116	1.062	1.066	0.966	0.655	0.525	90	90	72	13	-10	2.37E-06	3.61E-05	>1.00E-04		
MDA-MB-435	0.263	1.202	1.206	1.119	0.827	0.405	0.243	100	91	89	13	-14	1.58E-06	3.05E-05	>1.00E-04		
MDA-N	0.332	1.546	1.555	1.532	0.946	0.303	0.255	101	99	51	-9	-23	1.02E-06	7.09E-06	>1.00E-04		
BT-549	0.606	1.199	1.266	1.049	1.124	0.943	0.625	111	75	87	57	37	2.21E-05	>1.00E-04	>1.00E-04		
T-472	0.775	2.137	2.071	2.441	1.986	1.393	1.431	95	122	89	45	48	7.81E-06	>1.00E-04	>1.00E-04		












Mean Grapus



National Cancer Institute Developmental Therapeutics Program In-Vitro Testing Results

SC: D-673165-K/0-2/12	Experiment ID: 9502RM1c	Test Type: 8	Units: Molar
Report Date: March 28, 1995	Test Date: February 13, 1995	QNS: SHP	MC:
COMI: Phomopsinamine A	Stain Reagent: Dual-Pass	SSPL: 0FLC	

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities					Log10 Concentration					Percent Growth					GI50	TGI	LC50
			-8.0	-7.0	-6.0	-5.0	-4.0	-3.0	-2.0	-1.0	0.0	1.0	2.0	3.0	4.0					
Leukemia																				
CCRF-CEM	0.634	1.762	1.771	1.754	1.367	0.591	0.416	101	44	47	47	47	47	47	47	47	1.69E-06	6.09E-06	>1.00E-04	
HL-60 (TB)	0.592	1.622	1.679	1.580	0.864	0.371	0.312	106	44	46	47	47	47	47	47	47	4.56E-07	2.60E-06	>1.00E-04	
K-562	0.362	1.370	1.370	1.366	1.003	0.369	0.326	100	101	42	43	43	43	43	43	43	1.56E-06	6.92E-06	>1.00E-04	
MOLT-4	0.686	1.845	1.893	1.637	1.702	0.961	0.793	104	44	48	48	48	48	48	48	48	4.02E-06	>1.00E-04	>1.00E-04	
RPMI-8226	0.735	1.589	1.646	1.580	1.256	0.790	0.769	107	44	48	48	48	48	48	48	48	1.60E-06	>1.00E-04	>1.00E-04	
SR	0.486	1.032	1.056	0.859	0.536	0.412	0.366	104	44	48	48	48	48	48	48	48	2.04E-07	2.37E-06	>1.00E-04	
Non-Small Cell Lung Cancer																				
A549/ATCC	0.377	1.335	1.309	1.156	0.604	0.577	0.447	97	44	44	44	44	44	44	44	44	7.06E-07	>1.00E-04	>1.00E-04	
ECVX	0.402	1.029		1.021	0.900	0.659	0.629		44	44	44	44	44	44	44	44	5.81E-06	>1.00E-04	>1.00E-04	
HOP-62	0.391	0.653	0.673	0.696	0.822	0.659	0.619	96	44	44	44	44	44	44	44	44	2.70E-05	>1.00E-04	>1.00E-04	
HOP-92	0.761	1.116	1.214	1.167	1.116	1.110	0.970	108	44	44	44	44	44	44	44	44	>1.00E-04	>1.00E-04	>1.00E-04	
NCI-H226	0.607	0.664	0.900	0.674	0.729	0.525	0.446	114	44	47	47	47	47	47	47	47	8.95E-07	5.99E-06	>1.00E-04	
NCI-H23	0.419	1.166	1.174	1.124	0.966	0.669	0.674	101	44	47	47	47	47	47	47	47	3.85E-06	>1.00E-04	>1.00E-04	
NCI-H322H	0.624	1.566	1.602	1.576	1.312	0.644	0.785	104	44	47	47	47	47	47	47	47	2.90E-06	>1.00E-04	>1.00E-04	
NCI-H460	0.161	1.263	1.266	1.267	0.564	0.316	0.329	100	44	47	47	47	47	47	47	47	6.35E-07	>1.00E-04	>1.00E-04	
NCI-H522	0.413	1.073	1.071	1.084	0.691	0.642	0.316	100	44	47	47	47	47	47	47	47	3.93E-06	3.94E-05	>1.00E-04	
Colon Cancer																				
COLO 205	0.326	1.333	1.317	1.156	0.606	0.246	0.179	98	44	44	44	44	44	44	44	44	3.91E-07	3.40E-06	>1.00E-04	
HCC-2996	0.590	1.266		1.284	0.878	0.402	0.396		44	44	44	44	44	44	44	44	7.55E-07	3.73E-06	>1.00E-04	
HCT-116	0.161	1.304	1.219	1.229	0.729	0.343	0.256	93	44	44	44	44	44	44	44	44	9.87E-07	>1.00E-04	>1.00E-04	
HCT-15	0.317	1.667		1.574	1.115	0.614	0.393		44	44	44	44	44	44	44	44	1.76E-06	>1.00E-04	>1.00E-04	
HCT29	0.166	0.631	0.620	0.636	0.429	0.193	0.190	96	44	44	44	44	44	44	44	44	6.76E-07	>1.00E-04	>1.00E-04	
HCT12	0.294	1.445	1.397	1.230	0.595	0.367	0.301	96	44	44	44	44	44	44	44	44	3.70E-07	>1.00E-04	>1.00E-04	
SW-620	0.156	0.691	0.669	0.637	0.660	0.453	0.364	97	44	44	44	44	44	44	44	44	4.69E-06	>1.00E-04	>1.00E-04	
CNS Cancer																				
SF-268	0.463	1.431	1.410	1.366	1.079	0.920	0.755	98	44	44	44	44	44	44	44	44	6.77E-06	>1.00E-04	>1.00E-04	
SF-295	0.400	1.036	1.055	0.919	0.554	0.400	0.400	103	44	44	44	44	44	44	44	44	3.53E-07	>1.00E-04	>1.00E-04	
SF-539	0.367	0.660	0.669	0.636	0.640	0.213	0.153	102	44	44	44	44	44	44	44	44	1.06E-06	3.46E-06	2.09E-05	
SNB-19	0.571	1.385	1.372	1.336	1.063	0.617	0.742	96	44	44	44	44	44	44	44	44	2.22E-06	>1.00E-04	>1.00E-04	
SNB-75	0.361	0.626	0.664	0.650	0.470	0.406	0.430	116	44	44	44	44	44	44	44	44	6.51E-07	>1.00E-04	>1.00E-04	
U251	0.199	0.653	0.920	0.615	0.481	0.273	0.279	104	44	44	44	44	44	44	44	44	6.39E-07	>1.00E-04	>1.00E-04	
Melanoma																				
LOX IMVI	0.191	0.962		0.942	0.766	0.467	0.357		44	44	44	44	44	44	44	44	4.66E-06	>1.00E-04	>1.00E-04	
MALME-3M	0.464	1.037	1.035	0.912	0.760	0.631	0.610	100	44	44	44	44	44	44	44	44	1.57E-06	>1.00E-04	>1.00E-04	
M14	0.196	0.569	0.564	0.552	0.407	0.201	0.194	99	44	44	44	44	44	44	44	44	1.31E-06	3.46E-05	>1.00E-04	
SK-MEL-2	0.746	1.366	1.364	1.311	1.161	0.853	0.846	99	44	44	44	44	44	44	44	44	2.40E-06	>1.00E-04	>1.00E-04	
SK-MEL-26	0.576	1.166		1.102	0.944	0.725	0.653		44	44	44	44	44	44	44	44	1.94E-06	>1.00E-04	>1.00E-04	
SK-MEL-5	0.034	1.014	1.005	0.702	0.406	0.296	0.223	99	44	44	44	44	44	44	44	44	4.00E-07	>1.00E-04	>1.00E-04	
UACC-257	0.536	1.297	1.320	1.246	1.091	1.021	1.095	103	44	44	44	44	44	44	44	44	>1.00E-04	>1.00E-04	>1.00E-04	
UACC-62	0.577	1.662	1.621	1.770	1.255	1.029	1.047	97	44	44	44	44	44	44	44	44	1.43E-06	>1.00E-04	>1.00E-04	
Ovarian Cancer																				
IGR-OV1	0.515	1.689	1.633	1.631	1.445	1.071	0.864	95	44	44	44	44	44	44	44	44	8.26E-06	>1.00E-04	>1.00E-04	
OVCA-3	0.293	0.905	0.910	0.766	0.353	0.301	0.276	101	44	44	44	44	44	44	44	44	2.54E-07	1.53E-05	>1.00E-04	
OVCA-4	0.467	1.176	1.160	1.189	1.095	0.862	0.767	96	44	44	44	44	44	44	44	44	4.29E-05	>1.00E-04	>1.00E-04	
OVCA-5	0.393	0.667	0.861	0.914	0.641	0.514	0.565	99	44	44	44	44	44	44	44	44	1.02E-06	>1.00E-04	>1.00E-04	
OVCA-6	0.267	1.196		1.211	1.126	0.656	0.475		44	44	44	44	44	44	44	44	6.95E-06	>1.00E-04	>1.00E-04	
SK-OV-3	0.466	1.011	1.012	0.997	0.747	0.470	0.490	100	44	44	44	44	44	44	44	44	1.06E-06	>1.00E-04	>1.00E-04	
Renal Cancer																				
786-O	0.200	0.949	1.006	0.955	0.716	0.396	0.350	106	44	44	44	44	44	44	44	44	2.79E-06	>1.00E-04	>1.00E-04	
A496	1.061	1.413		1.470	1.263	1.007	0.910		44	44	44	44	44	44	44	44	1.45E-06	7.91E-06	>1.00E-04	
ACHN	0.406	1.460	1.476	1.476	1.157	0.970	0.603	102	44	44	44	44	44	44	44	44	1.66E-05	>1.00E-04	>1.00E-04	
Caki-1	0.466	0.950	0.861	0.663	0.630	0.665	0.701	66	44	44	44	44	44	44	44	44	6.95E-06	>1.00E-04	>1.00E-04	
RXFP-393	0.704	1.562	1.473	1.447	1.195	0.602	1.147	66	44	44	44	44	44	44	44	44		>1.00E-04	>1.00E-04	
SN12C	0.371	1.335	1.201	1.236	1.133	0.633	0.660	66	44	44	44	44	44	44	44	44	6.61E-06	>1.00E-04	>1.00E-04	
TK-10	0.627	1.091		1.090	1.142	0.967	0.965		44	44	44	44	44	44	44	44	>1.00E-04	>1.00E-04	>1.00E-04	
UO-31	0.593	1.476	1.492	1.513	1.452	1.066	1.060	102	44	44	44	44	44	44	44	44	>1.00E-04	>1.00E-04	>1.00E-04	
Prostate Cancer																				
PC-3	0.302	1.164	1.163	1.039	0.627	0.471	0.392	102	44	44	44	44	44	44	44	44	5.54E-07	>1.00E-04	>1.00E-04	
DU-145	0.339	1.029	1.031	0.964	0.563	0.299	0.344	100	44	44	44	44	44	44	44	44	5.60E-07		>1.00E-04	
Breast Cancer																				
MCF7	0.423	1.139	1.163	1.160	0.733	0.620	0.490	103	44	44	44	44	44	44	44	44	7.82E-07	>1.00E-04	>1.00E-04	
MCF7/ADR-RES	0.330	2.037	1.016	1.012	0.929	0.656	0.476	97	44	44	44	44	44	44	44	44	6.02E-06	>1.00E-04	>1.00E-04	
MDA-MB-231/ATCC	0.406	0.926	0.905	0.676	0.606	0.550	0.416	96	44	44	44	44	44	44	44	44	3.45E-06	>1.00E-04	>1.00E-04	
HS 578T	0.664	1.396	1.409	1.247	1.239	1.193	1.273	102	44	44	44	44	44	44	44	44	>1.00E-04	>1.00E-04		












[illegible]

National Cancer Institute Developmental Therapeutics Program


In-Vitro Testing Results

C: L 73165-K/0-1/5	Experiment ID: 9409SC89	Test Type: 8	Units: Molar
Port Date: October 27, 1994	Test Date: September 26, 1994	QNS:	MC:
MI: PHOMOPSINAMINE A	Stain Reagent: Dual-Pass	SSPL: 0FLC	

Panel/Cell Line	Time		Log10 Concentration								Percent Growth				GI50	TGI	LC50
	Zero	Ctrl	-8.0	-7.0	-6.0	-5.0	-4.0	-3.0	-2.0	-1.0	0.0	-1.0	-2.0	-3.0			
Leukemia																	
CCRF-CEM	0.250	0.793	0.779	0.757	0.516	0.218	0.232	97	93	49	-13	-7			9.50E-07	6.21E-06	>1.00E-04
HL-60 (TB)	0.213	0.691	0.710	0.706	0.461	0.101	0.096	104	103	56	-53	-55			1.13E-06	3.28E-06	9.47E-06
K-562	0.129	0.762	0.795	0.764	0.463	0.165	0.141	105	100	53	6	2			1.14E-06	>1.00E-04	>1.00E-04
MOLT-4	0.281	1.366	1.312	1.293	1.266	0.563	0.469	95	93	91	26	17			4.27E-06	>1.00E-04	>1.00E-04
RFMT-6226	0.196	0.676	0.919	0.899	0.640	0.255	0.258	106	103	65	9	-			1.86E-06		
SR	0.238	1.679	1.741	1.612	1.258	0.614	0.414	104	95	71	26	12			2.92E-06	>1.00E-04	>1.00E-04
Non-Small Cell Lung Cancer																	
A549/ATCC	0.361	1.610	1.591	1.608	1.016	0.598	0.584	99	100	53	19	18			1.19E-06	>1.00E-04	>1.00E-04
ERVK	0.686	1.691	1.579	1.652	1.493	1.126	1.074	89	96	80	44	38			6.79E-06	>1.00E-04	>1.00E-04
HOP-62	0.834	1.662	1.701	1.666	1.457	1.074	1.115	105	101	75	29	34			3.51E-06	>1.00E-04	>1.00E-04
NCI-H226	0.591	1.104	1.010	1.024	0.913	0.521	0.409	82	64	63	-12	-31			1.48E-06	6.95E-06	>1.00E-04
NCI-H23	0.455	1.521	1.625	1.647	1.288	0.571	0.413	110	112	78	11	-9			2.62E-06	3.48E-05	>1.00E-04
NCI-H322M	0.556	1.478	1.444	1.454	1.114	0.842	0.867	96	97	61	31	36			2.27E-06	>1.00E-04	>1.00E-04
NCI-H460	0.219	1.146	1.184	1.252	0.563	0.252	0.242	104	111	37	4	-35			6.72E-07	1.23E-05	>1.00E-04
NCI-H522	0.434	1.347	1.035	1.000	0.803	0.254	0.101	66	62	40	-42	-54			3.58E-07	3.11E-06	4.88E-05
Colon Cancer																	
COLO 205	0.208	1.003	1.074	1.023	0.495	0.163	0.059	109	103	36	-22	-72			6.17E-07	4.19E-06	3.65E-05
HCT-2998	0.262	0.891	0.947	0.974	0.642	0.221	0.107	109	113	60	-16	-59			1.37E-06	6.23E-06	6.16E-05
HCT-116	0.230	1.465	1.453	1.458	1.003	0.406	0.237	99	99	63	14	1			1.82E-06	>1.00E-04	>1.00E-04
HCT-15	0.717	2.858	2.699	2.730	2.337	1.121	0.760	93	94	76	19	2			2.83E-06	>1.00E-04	>1.00E-04
HT29	0.148	0.793	0.801	0.803	0.470	0.069	0.054	101	102	50	-53	-64			9.97E-07	3.04E-06	9.27E-06
IMD2	0.907	2.189	2.312	2.489	1.895	1.506	1.448	110	123	77	47	40			7.81E-06	>1.00E-04	>1.00E-04
SW-620	0.140	0.828	0.778	0.831	0.549	0.283	0.306	93	100	59	21	24			1.75E-06	>1.00E-04	>1.00E-04
CNS Cancer																	
SF-268	0.367	1.284	1.294	1.284	1.008	0.659	0.484	101	100	70	32	13			3.33E-06	>1.00E-04	>1.00E-04
SF-295	0.554	1.381	1.270	1.263	1.016	0.431	0.405	87	86	56	-22	-27			1.19E-06	5.18E-06	>1.00E-04
SF-539	0.517	1.568	1.540	1.592	1.331	0.423	0.291	97	102	77	-18	-44			1.94E-06	6.45E-06	>1.00E-04
SNB-19	0.567	1.633	1.488	1.571	1.265	0.866	0.800	86	94	65	27	20			2.44E-06	>1.00E-04	>1.00E-04
SNB-75	0.367	0.901	0.701	0.783	0.560	0.428	0.463	63	76	36	11	22			4.66E-07	>1.00E-04	>1.00E-04
U251	0.191	0.834	0.753	0.753	0.451	0.193	0.117	87	87	40	0	-39			6.25E-07	1.02E-05	>1.00E-04
Melanoma																	
LOX IMVI	0.279	1.064	1.050	1.071	0.852	0.578	0.503	96	101	73	36	28			4.55E-06	>1.00E-04	>1.00E-04
SK-MEL-2	0.563	1.498	1.516	1.462	0.905	0.555	0.530	102	96	37	-1	-6			5.96E-07	9.18E-06	>1.00E-04
SK-MEL-28	0.305	0.975	0.974	0.929	0.740	0.584	0.636	100	93	65	42	49			4.37E-06	>1.00E-04	>1.00E-04
SK-MEL-5	0.354	1.681	1.704	1.671	0.778	0.574	0.542	102	99	37	17	14			5.39E-07	>1.00E-04	>1.00E-04
UACC-257	0.709	2.006	1.941	1.943	1.564	1.111	1.252	95	95	66	31	42			2.85E-06	>1.00E-04	>1.00E-04
Ovarian Cancer																	
IGROV1	0.346	1.479	1.482	1.460	1.125	0.769	0.565	100	96	69	37	19			3.96E-06	>1.00E-04	>1.00E-04
OVCAR-5	0.377	0.670	0.881	0.834	0.671	0.432	0.451	102	93	60	11	15			1.58E-06	>1.00E-04	>1.00E-04
OVCAR-8	0.550	1.404	1.238	1.426	1.278	1.016	0.570	81	103	85	55	2			1.22E-05	>1.00E-04	>1.00E-04
SK-OV-3	0.423	0.902	0.908	0.935	0.705	0.551	0.490	101	107	59	27	14			1.88E-06	>1.00E-04	>1.00E-04
Renal Cancer																	
786-0	0.434	2.015	2.010	1.977	1.875	0.929	0.664	100	98	91	31	15			4.87E-06	>1.00E-04	>1.00E-04
A498	0.561	0.980	1.024	0.985	0.906	0.570	0.498	111	101	82	2	-11			2.54E-06	1.47E-05	>1.00E-04
ACHN	0.306	1.259	1.245	1.263	1.041	0.692	0.508	99	100	77	41	21			5.50E-06	>1.00E-04	>1.00E-04
SN12C	0.636	1.672	1.632	1.603	1.483	0.981	0.770	96	93	82	33	13			4.52E-06	>1.00E-04	>1.00E-04
TK-10	0.399	0.995	0.984	0.998	0.944	0.700	0.585	98	100	91	50	31			1.05E-05	>1.00E-04	>1.00E-04
Prostate Cancer																	
PC-3	0.952	3.445	3.372	3.208	1.952	1.405	1.413	97	90	40	18	18			6.36E-07	>1.00E-04	>1.00E-04
DU-145	0.459	1.595	1.581	1.587	0.999	0.572	0.467	99	99	48	10	1			8.97E-07	>1.00E-04	>1.00E-04
Breast Cancer																	
T-47D	0.259	1.158	1.285	1.306	0.600	0.390	0.347	114	116	38	15	10			7.02E-07	>1.00E-04	>1.00E-04
T-47D/ADR-RES	0.517	1.304	1.327	1.297	1.205	0.481	0.267	103	99	87	-7	-48			2.49E-06	8.44E-06	>1.00E-04
MDA-MB-231/ATCC	0.614	1.602	1.551	1.559	1.468	0.902	0.761	95	96	86	29	15			4.32E-06	>1.00E-04	>1.00E-04
HS 578T	0.586	1.164	1.091	1.067	0.877	0.623	0.558	87	87	50	6	-5			1.02E-06	3.67E-05	>1.00E-04
MDA-MB-435	0.283	0.780	0.912	0.636	0.240	0.128	0.191	126	71	-15	-55	-32			1.75E-07	6.66E-07	
MDA-N	0.332	1.424	1.348	1.278	0.312	0.139	0.169	93	87	-6	-58	-49			2.49E-07	8.61E-07	
BT-549	0.606	0.902	1.036	0.858	0.758	0.692	0.457	145	85	51	29	-25			1.14E-06	3.47E-05	>1.00E-04
T-47D	0.775	1.915	1.907	1.973	1.601	1.072	1.547	99	105	72	26	68				>1.00E-04	>1.00E-04



Mean Viaplus



Example 2

The following data show the effect of phomopsin A on several human cancer cell lines growing *in vivo* in hollow fibres inserted subcutaneously and intraperitoneally in athymic mice, as employed by NCI to assess the *in vivo* anticancer potential of compounds (Hollingshead *et al.*, 1995). Significant cell growth inhibition and cytocidal activity in demonstrated.

Capillary Hollow Fiber Assay for 673162

Report printed on 07-MAY-97

39

EXPT NO: HF591-0-HF		EVALUATION DATE: 15-DEC-95		HOST.: Athymic Nudes		IMPLANT DATE...: 08-DEC-95					
SEX....: F		SOURCE: APA		SOURCE: APA		STAGING DATE...: 11-DEC-95					
TREATMENT											
Grp No.	NSC No.	Dose/Units	Rt	Schedule	No. of Mice	No. of Fibers		WT/C	OVCA-3		
						IP	SC				
57	D-673162	30.00 mg/kg/dose	IP	QD 3 , Day 3	3	3	>100	67	49	35	79
58	D-673162	20.00 mg/kg/dose	IP	QD X , Day 3	3	3	37	58	85	36	>100

VEHICLES

Grp 57 -> NSC # 673162/ 1 (Dose= 30.00) : in Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt
 Grp 58 -> NSC # 673162/ 1 (Dose= 20.00) : in Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt

COMMENTS for HF591-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 07-MAY-97

EXPT NO: HF590-0-HF		EVALUATION DATE: 15-DEC-95		HOST...: Athymic Nudes		IMPLANT DATE...: 07-DEC-95	
SEX...: F		SOURCE/DISE...: 1		SOURCE: APA		STAGING DATE...: 11-DEC-95	
TREATMENT							
Grp No.	NSC No.	Dose/Units	Rt	Schedule	No. of Mice	No. of Fibers	WT/C
					NCI-H23		
					IP	SC	MDA-MB-231
					IP	SC	SW-620
57	D-673162	30.00 mg/kg/dose	IP	QD X 4, Day 4	3	3	81
					IP	SC	96
					IP	SC	72
					IP	SC	>100
58	D-673162	20.00 mg/kg/dose	IP	QD X 4, Day 4	3	3	>100
					IP	SC	44
					IP	SC	46
					IP	SC	>100
					IP	SC	>100

Report printed on 01-APR-96

41

EXPT NO: HF590-0-HF				EVALUATION DATE: 15-DEC-95				HOST...: Athymic Nudes				IMPLANT DATE...: 07-DEC-95									
SEX...: F				SOURCE/LINE...: 1				SOURCE: APA				STAGING DATE...: 11-DEC-95									
TREATMENT												WT/C (Net Growth)									
Grp		NSC		Dose/Units		Rt		Schedule		No. of Mice		No. of Fibers		NCI-H23		MDA-MB-231		SW-620			
No.		No.												IP		SC		IP		SC	
57		D-673162		30.00 mg/kg/dose		IP		QC x 4, Day 4		3		3		76		94		30		63	
														>100		>100		>100		>100	
58		D-673162		20.00 mg/kg/dose		IP		QC x 4, Day 4		3		3		>100		>100		28		29	
														>100		>100		>100		>100	

VEHICLES													
Grp 57 ->		NSC #		673162/		1 (Dose=		30.00) : In Saline + Tween 80 (0.05%)		(Unknown)		Inj. Vol.:0.1 ml/10gm body wt	
Grp 58 ->		NSC #		673162/		1 (Dose=		30.00) : In Saline + Tween 80 (0.05%)		(Unknown)		Inj. Vol.:0.1 ml/10gm body wt	

VEHICLES

Grp 57 -> NSC # 673162/ 1 (Dose= 30.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.: 0.1 ml/10gm body wt
 Grp 58 -> NSC # 673162/ 1 (Dose= 20.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.: 0.1 ml/10gm body wt

COMMENTS for HF590-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 01-APR-96

EXPT NO: HF591-0-HF
SEX: F
EVALUATION DATE: 15-DEC-95
SOURCE/LINE: 1
HOST: Athymic Nudes
SOURCE: APA
IMPLANT DATE: 08-DEC-95
STAGING DATE: 11-DEC-95

TREATMENT				WT/C (Net Growth)								
Grp No.	NSC No.	Dose/Units	Rt	Schedule *	No. of Mice	No. of Fibers	LOX IMVI		COLO 205		OVCAR-3	
							IP	SC	IP	SC	IP	SC
57	D-673162	30.00 mg/kg/dose	IP	QD X 4, Day 3	3	3	>100	>100	59	34	-18	22
58	D-673162	20.00 mg/kg/dose	IP	QD X 4, Day 3	3	3	>100	>100	48	81	-15	>100

VEHICLES

Grp 57 -> NSC # 673162/ 1 (Dose= 30.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt
Grp 58 -> NSC # 673162/ 1 (Dose= 20.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt

COMMENTS for HF591-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 07-MAY-97

43

EXPT NO: HF581-0-HF				EVALUATION DATE: 17-NOV-95				HOST...: Athymic Nudes				IMPLANT DATE....:									
SEX.....: F				SOURCE/DINE.....: 1				SOURCE: APA				STAGING DATE....: 13-NOV-95									
TREATMENT												#T/C									
Grp		NSC		Dose/Urits		R		Schedule		No. of Mice		No. of Fibers		NCI-H522		UACC-62		U251			
		No.												IP		SC		IP		SC	
D-673162				30.00 mg/kg/dose		1		Q1		4, Day 4		3		2		85					
												3		3							
B D-673162				20.00 mg/kg/dose		1		Q1		4, Day 4		3		2		70					
												3		3							
																>100		97		90	
																		>100		90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	
																				90	

VEHICLES

Grp 7 ->	NSC #	673162/	1 (Dose=	0.00)	: in Saline + Tween 80 (0.05%)	(Unknown)	Inj. Vol.:0.1 ml/10gm body wt
Grp 8 ->	NSC #	673162/	1 (Dose=	0.00)	: in Saline + Tween 80 (0.05%)	(Unknown)	Inj. Vol.:0.1 ml/10gm body wt

COMMENTS for HF581-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 01-APR-96

EXPT NO: HF581-0-HF				EVALUATION DATE: 17-NOV-95				HOST...: Athymic Nudes				IMPLANT DATE....:							
SEX.....: F				SOURCE/LINE.....: 1				SOURCE: APA				STAGING DATE....: 13-NOV-95							
TREATMENT												T/C (Net Growth)							
Grp No.	NSC No.	Dose/Units	Rt	Schedule	No. of Mice	No. of Fibers	NCI-H522		UACC-62		U251								
							IP	SC	IP	SC	IP	SC							
7	D-673162	30.00 mg/kg/dose	IP	QD X 4, Day 4	3	2	59	91	100	81	>100	91							
					3	3													
8	D-673162	20.00 mg/kg/dose	IP	QD X 4, Day 4	3	2	18	>100	95	79	83	98							
					3	3													

Capillary Hollow Fiber Assay for 673162

Report printed on 07-MAY-97

45

EXPT NO: HF582-0-HF		EVALUATION DATE: 17-NOV-95		HOST...: Athymic Nudes		IMPLANT DATE....:	
SEX....: F		SOURCE/TIME....: 1		SOURCE: APA		STAGING DATE....: 13-NOV-95	
TREATMENT:							
						SF/C	
						OVCR-5	
						MDA-MB-435	
						IP SC IP SC IP SC	
						(51)	
						89	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	
						>100	

VEHICLES

Grp 7 ->	NSC	673162/	1 (Dose= 10.00)	: in Saline + Tween 80 (0.05%) (Unknown)	Inj. Vol.: 0.1 ml/10gm body wt
Grp 8 ->	NSC	673162/	1 (Dose= 20.00)	: in Saline + Tween 80 (0.05%) (Unknown)	Inj. Vol.: 0.1 ml/10gm body wt

COMMENTS for HF582-0-HF

This experiment is within acceptat + quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 01-APR-96

46

EXPT NO: HF582-0-HF		EVALUATION DATE: 17-NOV-95		HOST...: Athymic Nudes		IMPLANT DATE....:				
SEX.....: F		SOURCE/LINE.....: 1		SOURCE: APA		STAGING DATE....: 13-NOV-95				
TREATMENT					WT/C (Net Growth)					
Grp No.	NSC No.	Dose/Units	Rt	Schedule	No. of Mice	MDA-MB-435		OVCAR-5		SF-295
						IP	SC	IP	SC	
7	D-673162	30.00 mg/kg/dose	IP	QD X 4, Day 4	3	2		38		
					3	3		62	58	90
										68
										>100
8	D-673162	20.00 mg/kg/dose	IP	QD X 4, Day 4	3	3		74	82	94
								87		>100
										>100

VEHICLES

Grp 7 -> NSC # 673162/ 1 (Dose= 30.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt
 Grp 8 -> NSC # 673162/ 1 (Dose= 20.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt

COMMENTS for HF582-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Report printed on 01-APR-96

47

EXPT NO: HF580-0-HF				EVALUATION DATE: 09-NOV-95				HOST...: Athymic Nudes				IMPLANT DATE....:													
SEX.....: F				SOURCE/LINE.....: 1				SOURCE: APA				STAGING DATE....: 05-NOV-95													
TREATMENT												WT/C (Net Growth)													
Grp		NSC		Dose/Units		Rt		Schedule		No. of Mice		No. of Fibers		LOX IMVI		COLO 205		OVCAR-3							
No.		No.								IP		SC		IP		SC		IP		SC					
7		D-673162		45.00 mg/kg/dose		IP		Q: < 4, Day 2		3		1		98		80		>100		64		61		>100	
8		D-673162		30.00 mg/kg/dose		IP		Q: < 4, Day 2		3		3		88		85		58		86		25		37	

VEHICLES											
Grp	7 ->	NSC #	673162/	1 (Dose=	15.00)	:	In Saline + Tween 80 (0.05%)	(Unknown)	Inj.	Vol.:0.1 ml/10gm	body wt
Grp	8 ->	NSC #	673162/	1 (Dose=	10.00)	:	In Saline + Tween 80 (0.05%)	(Unknown)	Inj.	Vol.:0.1 ml/10gm	body wt

VEHICLES

Grp 7 -> NSC # 673162/ 1 (Dose= 15.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt
 Grp 8 -> NSC # 673162/ 1 (Dose= 10.00) : In Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt

COMMENTS for HF580-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 01-APR-96

EXPT NO: HF579-0-HF			EVALUATION DATE: 09-NOV-95			HOST...: Athymic Nudes			IMPLANT DATE...: 02-NOV-95			
SEX...: F			SOURCE/LINE...: 1			SOURCE: APA			STAGING DATE...: 05-NOV-95			
TREATMENT						WT/C (Net Growth)						
Grp No.	NSC No.	Dose/Units	Rt	Schedule *	No. of Mice	NCI-H23			MDA-MB-231			SW-620
						IP	SC	IP	SC	IP	SC	
7	D-673162	45.00 mg/kg/dose	IP	QD X 4, Day 3	3	2	44	-41	>100	>100	78	78
8	D-673162	30.00 mg/kg/dose	IP	QD X 4, Day 3	3	3	60	21	>100	>100	97	86

VEHICLES

Grp 7 -> NSC # 673162/ 1 (Dose= 45.00) : in Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt
 Grp 8 -> NSC # 673162/ 1 (Dose= 30.00) : in Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt

COMMENTS for HF579-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 07-MAY-97

EXPT NO: HF580-0-HF		EVALUATION DATE: 09-NOV-95		HOST...: Athymic Nudes		IMPLANT DATE....:							
SEX.....: F		SOURCE/LINE.....: 1		SOURCE: APA		STAGING DATE....: 05-NOV-95							
TREATMENT													
Grp No.	NSC No.	Dose/Units	Rt	Schedule	No. of Mice	No. of Fibers		LOX IMVI		COLO 205		OVCAR-3	
						IP	SC	IP	SC	IP	SC	IP	SC
7	D-673162	45.00 mg/kg/dose	IP	Q: < 4, Day 2	3	1	98	84	>100	72	79	>100	
8	D-673162	30.00 mg/kg/dose	IP	Q: < 4, Day 2	3	3	90	88	67	89	60	66	

VEHICLES

Grp 7 -> NSC # 673162/ 1 (Dose= 15.00) : in Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt
 Grp 8 -> NSC # 673162/ 1 (Dose= 10.00) : in Saline + Tween 80 (0.05%) (Unknown) Inj. Vol.:0.1 ml/10gm body wt

COMMENTS for HF580-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Capillary Hollow Fiber Assay for 673162

Report printed on 07-MAY-97

EXPT NO: HF579-0-HF				EVALUATION DATE: 09-NOV-95				HOST...: Athymic Nudes				IMPLANT DATE....: 02-NOV-95			
SEX.....: F				SOURCE/LINE.....: 1				SOURCE: APA				STAGING DATE....: 05-NOV-95			
TREATMENT												PT/c			
								NCI-H23				MDA-MB-231			
								IP				IP			
								SC				SC			
								No. of Mice				No. of Fibers			
								3				2			
				45.00 mg/kg/dose				IP QD X 4, Day 3				>100			
				30.00 mg/kg/dose				IP QD X 4, Day 3				>100			
								77				65			
								99				98			
								82				83			
												SW-620			
								IP				IP			
								99				98			
								89							

VEHICLES

Grp 7 ->	NSC #	673162/	1 (Dose= 45.00)	: in Saline + Tween 80 (0.05%)	(Unknown)	Inj. Vol.: 0.1 ml/10gm body wt
Grp 8 ->	NSC #	673162/	1 (Dose= 30.00)	: in Saline + Tween 80 (0.05%)	(Unknown)	Inj. Vol.: 0.1 ml/10gm body wt

COMMENTS for HF579-0-HF

This experiment is within acceptable quality control parameters and is considered valid.

Finally, it is to be understood that various alterations, modifications and/or additions may be introduced into the composition and/or arrangement of steps previously described without departing from the spirit or ambit of the invention.

5

DATED: 29 September, 1999

PHILLIPS ORMONDE & FITZPATRICK

Attorneys for:

COMMONWEALTH SCIENTIFIC &

10 **INDUSTRIAL RESEARCH ORGANISATION**

